Kosmos
Karl-Marx-Allee 131a
10243 Berlin
Germany

www.facebook.com/worldhealthsummit
www.linkedin.com/company/whs-foundation-gmbh
www.twitter.com/WorldHealthSmt
Hashtag: #WHS2017
WORLD HEALTH SUMMIT
BERLIN, GERMANY
OCTOBER 15-17, 2017
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speakers/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 –</td>
<td>Healthy and Resilient Cities</td>
<td>PD 01</td>
<td>Page 40</td>
</tr>
<tr>
<td>11:30</td>
<td>Gender Equality within the Global Health Workforce</td>
<td>SAAL 6</td>
<td>EUROPE</td>
</tr>
<tr>
<td></td>
<td>Improving Pandemic Preparedness and Response</td>
<td>SAAL 10</td>
<td>ASIA</td>
</tr>
<tr>
<td></td>
<td>Tackling Barriers to Cancer Treatment and Care</td>
<td>SAAL 4</td>
<td>AFRICA</td>
</tr>
<tr>
<td>11:30 –</td>
<td>Long-term and End-of-Life Care in Aging Societies</td>
<td>WS 04a</td>
<td>Page 50</td>
</tr>
<tr>
<td>13:00</td>
<td>Noncommunicable Diseases</td>
<td>PD 04</td>
<td>Page 46</td>
</tr>
<tr>
<td>13:00 –</td>
<td>After the US COP21 Withdrawal</td>
<td>PD 06</td>
<td>Page 56</td>
</tr>
<tr>
<td>14:30</td>
<td>Artificial Intelligence in Health</td>
<td>PD 04</td>
<td>Page 46</td>
</tr>
<tr>
<td></td>
<td>Defining an EU Global Health Strategy</td>
<td>PD 04</td>
<td>Page 46</td>
</tr>
<tr>
<td></td>
<td>The Human Cell Atlas as a Basis for Novel Therapies</td>
<td>PD 04</td>
<td>Page 46</td>
</tr>
<tr>
<td>15:00 –</td>
<td>Precision Medicine and Population Health</td>
<td>PD 03</td>
<td>Page 62</td>
</tr>
<tr>
<td>16:30</td>
<td>Migration and Global Health Policy</td>
<td>PD 03</td>
<td>Page 62</td>
</tr>
<tr>
<td>17:00 –</td>
<td>Opening Ceremony</td>
<td>KEY 01</td>
<td>Page 72</td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Reception</td>
<td>KEY 01</td>
<td>Page 72</td>
</tr>
</tbody>
</table>
## Monday | October 16, 2017

<table>
<thead>
<tr>
<th>SAAL 1</th>
<th>SAAL 6</th>
<th>SAAL 10</th>
<th>SAAL 2</th>
<th>SAAL 4</th>
<th>SAAL 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>RUDOLF VIRCHOW</td>
<td>EUROPE</td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
</tr>
</tbody>
</table>

### 09:00 – 10:30
- **Big Data for Health Governance**
  - MB Alliance
  - Monash University
  - SAP SE
- **Innovative New Ways in Fighting NTDs**
  - German Network against Neglected Tropical Diseases
  - German Association of Research-based Pharmaceutical Companies
- **New Structures for Translational Research**
  - German Centers for Health Research
  - Helmholtz Association of German Research Centers e.V.
- **Diabetes, Metabolism & Obesity**
  - Charité – Universitätsmedizin Berlin
  - Sanofi
- **Global Health Security Engagement in Conflict and Crisis Situations**
  - Bundeswehr Command and Staff College
  - Center for Global Health Engagement
  - Harvard Medical School
  - King’s College London

**Coffee Break (30 min)**

### 11:00 – 12:30
- **Health Policy in the G7/G20**
  - Johns Hopkins Bloomberg School of Public Health
  - MB Alliance
- **The Beauty of Impact**
  - Bayer Science & Education Foundation

**KEY 02 | Page 86**

### 12:30 – 14:00
- **Lunch Break (90 min)**
- **World Health Summit Startup Track Pitch Competition**

**KEY 03 | Page 92**

### 14:00 – 16:00
- **Innovations in Digital Health**
  - MB Alliance
  - SAP SE
  - University of Coimbra
- **Vaccination Apathy**
  - London School of Hygiene & Tropical Medicine
  - MB Alliance
  - Pfizer Inc

**Coffee Break (30 min)**

### 16:30 – 18:00
- **Global Health Security**
  - Munich Security Conference
  - Pfizer Inc
- **Global Health Financing**
  - SEEK Development, Strategic and Organizational Consultants GmbH
- **Why must Patient Safety start in the Community?**
  - European Resuscitation Council
  - German Resuscitation Council
  - MB Alliance
  - National University of Singapore
  - University Hospital of Cologne
- **Sepsis and Infections in the 21st Century**
  - Leibniz Association
- **Promoting R&D Capacity and Manufacturing**
  - European and Developing Countries Clinical Trials Partnership
  - Deutsche Gesellschaft für Internationale Zusammenarbeit
  - World Health Organization

**18:30 – 23:00 World Health Summit Night | Page 106**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>SAAL 1</th>
<th>SAAL 2</th>
<th>SAAL 3</th>
<th>SAAL 4</th>
<th>SAAL 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 10:30</td>
<td>The Health Impact of War &amp; Terror&lt;br&gt;International Committee of the Red Cross&lt;br&gt;Max Planck Society&lt;br&gt;Robert Koch Institute&lt;br&gt;University of Montreal</td>
<td>PD 06</td>
<td>WS 21</td>
<td>WS 22</td>
<td>WS 23</td>
<td>WS 24</td>
</tr>
<tr>
<td></td>
<td>One Health&lt;br&gt;Max Planck Society&lt;br&gt;Tehran University of Medical Sciences&lt;br&gt;The Graduate Institute of International and Development Studies</td>
<td>SAAL 6</td>
<td>SAAL 10</td>
<td>SAAL 2</td>
<td>SAAL 4</td>
<td>SAAL 5</td>
</tr>
<tr>
<td></td>
<td>Equitable Access to Universal Health Coverage &amp; Care&lt;br&gt;M8 Alliance&lt;br&gt;Tehran University of Medical Sciences&lt;br&gt;The Graduate Institute of International and Development Studies</td>
<td>SAAL 10</td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
</tr>
<tr>
<td></td>
<td>Growing from Response to Preparedness&lt;br&gt;Foundation for Innovative New Diagnostics</td>
<td>SAAL 10</td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
</tr>
</tbody>
</table>

Coffee Break (30 min)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>SAAL 1</th>
<th>SAAL 2</th>
<th>SAAL 3</th>
<th>SAAL 4</th>
<th>SAAL 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:30</td>
<td>Vaccine Research and Development&lt;br&gt;Coalition for Epidemic Preparedness&lt;br&gt;Innovations&lt;br&gt;London School of Hygiene &amp; Tropical Medicine&lt;br&gt;M8 Alliance&lt;br&gt;Max Planck Institute for Infection Biology</td>
<td>KEY 04</td>
<td>PD 06a</td>
<td>PD 06a</td>
<td>PD 06a</td>
<td>PD 06a</td>
</tr>
<tr>
<td></td>
<td>Shaping the Future of Digital Healthcare in the Developing World&lt;br&gt;Deutsche Gesellschaft für Internationale Zusammenarbeit</td>
<td>SAAL 1</td>
<td>SAAL 2</td>
<td>SAAL 3</td>
<td>SAAL 4</td>
<td>SAAL 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
<td>OCEANIA</td>
</tr>
</tbody>
</table>

Coffee Break (30 min)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>SAAL 1</th>
<th>SAAL 2</th>
<th>SAAL 3</th>
<th>SAAL 4</th>
<th>SAAL 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 14:00</td>
<td>Lunch Break (90 min)</td>
<td>KEY 05</td>
<td>PD 06b</td>
<td>PD 06b</td>
<td>PD 06b</td>
<td>PD 06b</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SAAL 1</td>
<td>SAAL 2</td>
<td>SAAL 3</td>
<td>SAAL 4</td>
<td>SAAL 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
<td>OCEANIA</td>
</tr>
</tbody>
</table>

Coffee Break (30 min)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>SAAL 1</th>
<th>SAAL 2</th>
<th>SAAL 3</th>
<th>SAAL 4</th>
<th>SAAL 5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Making the Case for Open Contracting in Health&lt;br&gt;International Federation of Pharmaceutical Manufacturers &amp; Associations</td>
<td>SAAL 1</td>
<td>SAAL 2</td>
<td>SAAL 3</td>
<td>SAAL 4</td>
<td>SAAL 5</td>
</tr>
<tr>
<td></td>
<td>Antimicrobial Resistance&lt;br&gt;German Federal Ministry for Economic Cooperation and Development&lt;br&gt;Deutsche Gesellschaft für Internationale Zusammenarbeit</td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
<td>OCEANIA</td>
</tr>
<tr>
<td></td>
<td>Healthy Exchange: Hospital Partnerships for Global Health&lt;br&gt;European ESTHER Alliance&lt;br&gt;London School of Hygiene &amp; Tropical Medicine&lt;br&gt;M8 Alliance&lt;br&gt;Monash University&lt;br&gt;Tehran University of Medical Sciences&lt;br&gt;Université Paris Descartes&lt;br&gt;Université Sorbonne&lt;br&gt;Paris Cité&lt;br&gt;University of Geneva</td>
<td>SAAL 2</td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
</tr>
<tr>
<td></td>
<td>Emerging Trends in Public Health Education</td>
<td>SAAL 5</td>
<td>ASIA</td>
<td>AMERICA</td>
<td>AFRICA</td>
<td>OCEANIA</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welcome Messages</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key Facts</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mission</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topics 2017</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Health Summit Presidents</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Health Summit Scientific Committee</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Health Summit Ambassadors and Council</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M8 Alliance</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Health Summit Startup Track</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Health Summit Night</td>
<td>34</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Voices in Global Health</td>
<td>36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program, Sunday, October 15, 2017</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program, Monday, October 16, 2017</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program, Tuesday, October 17, 2017</td>
<td>109</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Information</td>
<td>141</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Directions</td>
<td>142</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accomodation</td>
<td>144</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venue</td>
<td>145</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A–Z</td>
<td>146</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City of Berlin</td>
<td>150</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker Index</td>
<td>152</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Institutions</td>
<td>154</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partners</td>
<td>156</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Media Information</td>
<td>161</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contacts</td>
<td>162</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imprint</td>
<td>166</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Global challenges call for global responses. This applies also and in particular to the fight against infectious diseases. These diseases do not end at national borders. The global increase in mobility also increases risk that they will spread. The international community knows all too well that epidemics can have disastrous consequences. That is why, this year, Germany made Global Health Policy a focus of its G20 Presidency. Under the motto “Shaping an interconnected world”, we and our partners have successfully sent a strong signal of cooperation. The aim is to strengthen the world’s healthcare systems. This means guaranteeing both extensive preventive measures and, in the event of a crisis, a rapid international response. The United Nations and the World Health Organization are crucial for coordinating these efforts. Their structures must be made fit for this purpose, and they must receive sufficient funding. To effectively fight global health crises, all actors need to cooperate efficiently. A key requirement is of course that countries have well functioning healthcare systems in place. It is not only important at local level, but also in the global interest, that healthcare specialists on the ground can detect outbreaks of dangerous diseases at an early stage.

That is why one of the goals of the 2030 Agenda for Sustainable Development is to ensure universal healthcare. This includes global responses in the fight against antimicrobial resistance. All our efforts to improve healthcare structures will amount to very little if therapies become ineffective. Antibiotics must therefore be used responsibly, so that the spread of resistant bacteria can be limited. Moreover, new vaccines and antibiotics must be developed. In tackling this great challenge, it is paramount that we coordinate our support for research and development, and that we employ our resources in a targeted way. I am therefore delighted that the G20 countries have agreed to establish a global research initiative.

Shaping an interconnected world: To fully live up to this responsibility and give globalisation a human dimension, we must first have a comprehensive dialogue. The World Health Summit has become a well and widely respected international forum when it comes to the joint search for effective responses to global health issues. I want to express my heartfelt thanks for the valuable work you are doing, by contributing your knowledge and experience to this common effort. As patron of the World Health Summit 2017, I would like to welcome all the participants to Berlin.

Angela Merkel
Chancellor of the Federal Republic of Germany
In today’s connected and interdependent world, health threats must be tackled globally. An integrated approach must be taken. This global approach to health is one of the G20’s key priorities.

The Sustainable Development Goals adopted as part of the 2030 Agenda for Sustainable Development of the United Nations are aimed at every country in the world in a global, partner-based and universal approach. Goal 3 on Health, in particular, aims to stamp out the epidemics of AIDS, tuberculosis, malaria and other communicable diseases and to effectively fight noncommunicable diseases by 2030. The objective is to ultimately provide universal health coverage, with access to safe, efficient, affordable vaccines and medicines. To make this happen, it is essential to support the research and development of new vaccines.

The resurgence in resistance to antibiotics, which the World Health Organization, the G20 and the European Union see as an absolute priority, has proven that we must never stop being vigilant. To this end, France has joined forces with Germany to create a global R&D platform on antibiotic resistance. This must be carried forward in an integrated, systemic and unified approach. We must link environmental, public and animal health at local, national and global levels based on the concept of “One Health”. France committed to this at the G20 in Hamburg and the Franco-German Council of Ministers in Paris. I want priority to be given to developing new medicines, but also to R&D for new methods of diagnosis.

Personalized medicine and global health must receive an integrated response, involving medicine, biology, food, urbanization, environment and education. To achieve this, cooperation between states, the scientific, economic and medical stakeholders, and civil society is essential and must be planned over the long term. The World Health Summit has become a key forum for addressing these issues in a cross-cutting manner by bringing together these actors on an international level.

The terms of globality and universality are now more than ever associated with health:
• international preventive measures;
• quality care for all, accessible to all;
• renewed support for health as a driver of development, growth and stability;
• and an ambitious research policy, which is a source of progress.
These are principles to which France is committed, and which it supports in international bodies.

As patron of this Summit, I would like to join with the Chancellor of the Federal Republic of Germany and the President of the European Commission in wishing you all an excellent and productive meeting.

Emmanuel Macron
President of the Republic of France
As we get older, we naturally become more conscious of our health. This year the European Union celebrated its 60th birthday - a time both for celebration and reflection on the health of our Union.

The good news is that Europeans are living longer than ever before. Life expectancy has risen by a decade for both men and women in the last fifty years. That is in large part thanks to the progress we have made in healthcare standards, investment in prevention and welfare and pioneering research enabling breakthroughs in the fight against disease and illness.

However, as this year’s World Health Summit themes show, there is no room for complacency when it comes to tackling the new and urgent health challenges facing Europe and the rest of the world. Poverty, rising inequalities and migration flows are all issues which have a significant impact on global health. Ensuring that as many citizens of the world have access to healthcare is a responsibility for us all. The same goes for research into prevention, sustainable development and understanding the health impact of an older and more urban population.

That shows the true importance of the World Health Summit as a hub for expertise, innovation and cooperation. Here in Europe we are committed to leading the way. This year we brought together networks of medical experts and hospitals in 26 countries to ensure that as many of the 30 million people in the EU suffering from 8,000 rare diseases each year have access to the specialised care and treatment they need. We also signalled our strong and unequivocal commitment to promoting vaccination as a driving force for improved health in Europe and the wider world.

Our joint resolve to protect the health and well-being of all of our citizens now and in the future is stronger than ever. As with every year, the World Health Summit is a key milestone in our efforts. I urge you all to make the most of the week and wish you successful event full of healthy discussions.

Jean-Claude Juncker
President of the European Commission
Dear Friends and Colleagues,

The year 2017 has been another amazing year packed with scientific progress. Genome editing of immune cells is making gene therapy of cancer a reality. A continued digital revolution is providing a massive accumulation of new data related to health and disease. Great advances toward personalized and precision medicine and a plethora of applications are arising from new methods in cell biology and medical technology. Those are just a few of the central topics at the World Health Summit in 2017. But unfortunately, despite these great achievements—and their parallels in the acceleration of the innovation cycle for medical technologies and equipment—the global burden of disease has remained largely unchanged.

We should be able to translate all this progress in science into better standards of health for all, but too many obstacles remain. Noncommunicable diseases such as hypertension, cancer, diabetes, and neurodegenerative conditions remain the leading causes of death worldwide. Epidemics are turning into pandemics through the increasing interconnectivity of our world and the globalization of lifestyles. All the while, millions of people are fleeing war, terror, natural disasters, and poverty. It is growing harder to achieve and maintain effective healthcare in rural areas and spreading megacities.

What can we do?

“Give me but a firm spot on which to stand, and I shall move the earth,” said the great Greek mathematician Archimedes. What sort of spot would be required to improve global health? This firm spot can only be the reliable international cooperation of all stakeholders—from academics to politicians, from the private sector and civil society. A milestone in this quest was the prominent position health topics assumed on the agendas of this year’s G7 and G20 meetings. But we cannot leave things there; it is our shared responsibility to turn discussions into action.
The World Health Summit 2017 brings together stakeholders and decision-makers from all sectors, and from all over the world. Our combined forces can achieve change, and provide the firm spot from which to improve health worldwide. The World Health Summit Regional Meeting held last May in the Canadian city of Montreal demonstrated what can be achieved if we unite the brightest minds in health. The World Health Summit in Berlin will carry this momentum forward to contribute to an agenda by which health can be improved globally.

As presidents of the World Health Summit 2017, we cordially invite you to make the best of this unique event, which will feature over 40 sessions, more than 200 expert speakers and 2,000 participants from 100 countries. Join us to make this world a healthier world.

We look forward to welcoming you at the World Health Summit 2017 in Berlin!

Helène Boisjoly  
World Health Summit  
President 2017  
University of Montreal  
Canada  

Detlev Ganten  
World Health Summit  
Founding President  
Charité – Universitätsmedizin Berlin
“We need to strive towards the highest possible level of healthcare in order to best help our patients and all those in need of medical treatment. Simultaneously, we must develop superb preventive strategies to ensure that the world’s population remains healthy in the first place. The World Health Summit brings together experts from across the globe to improve both healthcare and prevention. We are thus extremely excited to welcome such an array of excellent minds to Berlin and to the Charité for the annual summit in October.”

Karl Max Einhäupl
Chief Executive Officer
Charité – Universitätsmedizin Berlin

“Forum such as the World Health Summit are essential if we are to keep up with the pace of new trends and possibilities that have emerged concerning life-long medical education. For many years now, the World Health Summit’s agenda has prioritized the education of tomorrow’s healthcare workforce. The summit has thus emerged as a leading voice in this matter, reaching students and institutions across the globe.”

Axel Radlach Pries
Dean
Charité – Universitätsmedizin Berlin

“The healthcare industry is increasingly faced with an ever growing demand for cost intensive, high-tech solutions for unmet medical needs. Simultaneously, resources remain limited and tight budgets must be met. The World Health Summit unites international medical academics, healthcare experts and key political protagonists within a context of information exchange, open discussion and resourceful networking. It thus serves as an excellent forum for developing constructive, sustainable and prompt answers to this contemporary global challenge.”

Astrid Lurati
Hospital Director
Charité – Universitätsmedizin Berlin
“The world of healthcare is changing rapidly and we need to rethink our approaches on all levels. First and foremost we should work towards a system that focuses on the medical outcomes of our patients. We face an unprecedented opportunity in the form of vast amounts of medical data. We need forums like the World Health Summit in order to connect to global experts and thus channel the potential of this data.”

Ulrich Frei
Medical Director
Charité – Universitätsmedizin Berlin

“The Berlin Institute of Health aims to create an innovative translational research commons of Charité and Max Delbrück Center, enhancing personalized medicine and advanced therapies research in Germany and for the global population at large. Pursuing this agenda, the World Health Summit is an excellent platform to exchange and enhance experience and research findings.”

Rolf Zettl
Chief Executive Officer
Berlin Institute of Health

“The Max Delbrück Center for Molecular Medicine and the Berlin Institute of Health are both committed to translating groundbreaking research results into clinical applications. By achieving this we can contribute to improving peoples’ health and quality of life. Cooperation and exchange among the involved players is an important element in achieving world-class translational research. For this, the World Health Summit is the ideal forum to present our results and ideas and discuss them with leading health experts.”

Martin Lohse
Scientific Director, Max Delbrück Center for Molecular Medicine, and Spokesperson of the Executive Board, Berlin Institute of Health
The World Health Summit is one of the world’s most prominent strategic forums for global health. The interdisciplinary event takes place within an atmosphere of academic freedom and is the premiere international platform for exploring strategic developments and decisions in the area of healthcare.

**Facts at a glance**
- Annual event in Berlin
- Patronage: German Chancellor Angela Merkel, President of the Republic of France Emmanuel Macron and European Commission President Jean-Claude Juncker
- Mission: improve healthcare all over the world
- Participants: 2,000 from 100 countries
- Founded: 2009 on the 300th anniversary of the founding of the Charité Hospital
- Organized by the WHS Foundation GmbH, a subsidiary of Charité – Universitätsmedizin Berlin

**Participants**
- Top-level researchers and members of the scientific community
- High-profile political decision-makers
- Executives and representatives from the healthcare system
- Leaders of the health-related industry and technology sector
- Representatives of civil society and foundations
- Students and young professionals from all health-related fields

**Social Media**
- [www.facebook.com/worldhealthsummit](http://www.facebook.com/worldhealthsummit)
- [www.twitter.com/WorldHealthSmt](http://www.twitter.com/WorldHealthSmt)
- [www.linkedin.com/company/whs-foundation-gmbh](http://www.linkedin.com/company/whs-foundation-gmbh)
- Hashtag: #WHS2017
VISION AND GOALS

The World Health Summit is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies. Through the InterAcademy Partnership (IAP) for Health, it is organized in collaboration with national academies of science in 97 countries.

The World Health Summit aims to improve health all over the planet, catalyzing that process through collaboration and open dialogue, and steering tomorrow’s agenda to improve research, education, healthcare, and policy outcomes.

It brings together researchers, physicians, key government officials, and representatives from industry as well as from NGOs and healthcare systems all over the world to address the most pressing issues facing every facet of healthcare and medicine in the upcoming decade and beyond.

The World Health Summit is built on the stable foundation of academic excellence provided by the M8 Alliance and has strong political support from a variety of partners at global, national and state levels.

MAIN GOALS AND PARTNERSHIP ASSETS

The M8 Alliance is improving global health through pursuit of five strategic goals:

- Bring together all stakeholders at the level of equals
- Establish a unique and sustainable high-level forum and network
- Help define the future of medicine, research and healthcare
- Find answers to major health challenges – both today and tomorrow
- Make global recommendations and set health agendas worldwide
Health Policy in the G7/G20: The Future of Global Health Governance
Healthcare has developed into a key policy issue that is discussed at both national and international levels. In 2017, the G20 will for the first time include a meeting of national Health Ministers in a forum set to cover topics like health security and Antimicrobial Resistance. The health governance issues inherent in the Sustainable Development Goals have underlined how increasing financial and political commitments are central to solving global health challenges.

Global Health Security: Policy Responses to Planetary Challenges
If we want to create a world that is more secure from infectious diseases and other threats to health, the global community must enhance its collective capacity for resilience, and respond more quickly to crises. To reach those goals, we must first create and nurture policy synergies between nation-states and international organizations, and then move towards improving communication activities with both public and private stakeholders.

Healthy and Resilient Cities: Rethinking Urban Transformation
Urban populations face many health risks, among them pollution, noise, overcrowding, traffic, insufficient access to drinking water and sanitary facilities, crime, and infectious disease. A major challenge is integrating health into urban planning, investment and policy decisions – and making it a transformative driver of sustainable development at the city level.

Vaccine Research and Development: Challenges and Opportunities
When it comes to fighting infectious diseases, vaccines offer top economic and social value. Intensified global efforts to step up vaccine research and development are therefore a must, especially for neglected tropical diseases. A central challenge is that in some developed countries, where popular perceptions no longer view infection or epidemics as a serious risk, mindsets will need to change.

Strengthening Innovation and Health Systems in Africa
Achieving the Sustainable Development Goals will require significant innovations regarding investments and partnerships with Africa. Attaining these goals will only be possible via utilizing integrated approaches to health, development and security, as well as consensus-building based upon knowledge exchange. Tools and approaches used for goals such as ending the AIDS epidemic in Africa could be used for a process of social transformation which will contribute to achieving other SDGs without leaving anyone behind.

Big Data for Health Governance: Benefits, Frameworks and Ethics
Data is now a cornerstone of the healthcare industry. It documents everything from blood pressure readings and surgical records to insurance claims, immunization histories, patient demographics and receipts of payment. But even though Big Data can bridge the gap between healthcare delivery and population health and improve many health outcomes through enhanced methods of research, the detailed collection of personal information poses ethical, regulatory and technical challenges.
PRESIDENTS 2017

HÉLÈNE BOISJOLY
Dean
Faculty of Medicine, University of Montreal, Canada

DETLEV GANTEN
Honorary Chairman of the Board, Charité Foundation, Germany

FORMER PRESIDENTS

2016
ANTOINE FLAHULT
Director
Institute of Global Health, University of Geneva, Switzerland

2015
SHUNICHI FUKUHARA
Dean
School of Public Health, Kyoto University, Japan

2014
JOSÉ OTÁVIO AULER JR.
Dean
Faculty of Medicine, University of São Paulo, Brazil

2013
JOHN EU-LI WONG
Chief Executive Officer
National University Health System, Singapore

2012
MICHAEL J. KLAG
Former Dean
Johns Hopkins Bloomberg School of Public Health, USA

2011
STEVE WESSELINGH
Dean
Monash University, Melbourne, Australia

2010
STEVEN K. SMITH
Pro Rector, Health
Imperial College London, United Kingdom

2009
AXEL KAHN
Dean
Sorbonne Paris Cité, France
The World Health Summit Scientific Committee consists of the M8 Alliance Executive Committee (see page 27) and these members of the World Health Summit Council:

**CO-CHAIRS**

HÉLÈNE BOISJOLY  
Dean  
Faculty of Medicine, University of Montreal, Canada

STEFAN KAUFMANN  
Director  
Max Planck Institute for Infection Biology, Germany

**MEMBERS**

RIFAT ATUN  
Director, Global Health Systems Cluster  
Harvard T.H. Chan School of Public Health, USA

DAVID DE KRETSER  
Professor, Reproductive Endocrinology  
Monash University, Australia

BÄRBEL-MARIA KURTH  
Director, Epidemiology and Health Monitoring  
Robert Koch Institute, Germany

KLAUS LINDPAINTNER  
Scientific Director  
King Abdullah International Medical Research Center, Al Ahsa-Jeddah-Riyadh, Saudi Arabia

EDUARDO PISANI  
Former Executive Director  
International Federation of Pharmaceutical Manufacturers & Associations, Switzerland

ERICH R. REINHARDT  
Chair of the Board  
Medical Valley EMN e.V., Germany

HEINZ RIEDERER  
Managing Director  
iNG innovation. Nachhaltigkeit. Gesundheit, Germany

GÜNTER STOCK  
President  
ALLEA  
All European Academies, Germany
WORLD HEALTH SUMMIT AMBASSADORS

MANFRED DIETEL
Director, Comprehensive Cancer Center
Charité - Universitätsmedizin Berlin, Germany

ECKART VON HIRSCHHAUSEN
Medical Doctor and Cabaret
Germany

MICHAEL RABBOW
Senior Advisor
E&P Focus Africa Consulting,
Germany

REINHARD SCHÄFERS
Former Ambassador
Federal Republic of Germany

ANSGAR TIETMEYER
Former Head of Public Affairs
Deutsche Bank AG, Germany

CHARLES YANKAH
Chairman of the Board
Afrika Kulturinstitut e.V.,
Berlin, Germany

COUNCIL

CHAIR

ILONA KICKBUSCH
The Graduate Institute of International and Development Studies, Switzerland

MEMBERS

ALA ALWAN
University of Washington,
Department of Global Health

RIFAT ATUN
Harvard T.H. Chan School of Public Health

TILL BÄRNIGHAUSEN
Heidelberg University

INGO BEHNEL
German Federal Ministry of Health

CHRISTOPH BEIER
Deutsche Gesellschaft für Internationale Zusammenarbeit

CHRISTOPH BENN
The Global Fund to Fight AIDS, Tuberculosis and Malaria

TOBIAS BERGNER
German Federal Foreign Office

ARNAUD BERNAERT
World Economic Forum

CATHERINA BÖHME
Foundation for Innovative New Diagnostics
THOMAS B. CUENI
Int. Federation of Pharmaceutical Manufacturers & Associations

MANFRED DIETEL
Charité - Universitätsmedizin Berlin

KLAUS DUGI
Ferring Pharmaceuticals

TIMOTHY EVANS
World Bank

ROLAND GÖHDE
German Healthcare Partnership

JÖRG HACKER
German National Academy of Sciences Leopoldina e.V.

ANDREW HAINES
London School of Hygiene & Tropical Medicine

MARGARET HAMBURG*
American Association for the Advancement of Science

INGRID-GABRIELA HOVEN*
German Federal Ministry of Economic Cooperation and Development

ZSUZSANNA JAKAB
World Health Organization

ASHISH JHA
Harvard Global Health Institute

 STEFAN KAUFMANN
Max Planck Institute for Infection Biology

SUSANNA KRÜGER
Save the Children Germany

BÄRBEL KURTH
Robert Koch Institute

STEVE LANDRY
Bill & Melinda Gates Foundation

YVES LEVY
Institut national de la santé et de la recherche médicale

MARION LIESER
Oxfam Germany

KLAUS LINDEPAINTER
King Abdullah International Medical Research Center

LUZ LOURES
UNAIDS

PHILIPPE MEYER
Descartes University

JÜRGEN MLYNEK
Falling Walls Foundation

MATSHIDISO REBECCA MOETI*
World Health Organization

BERND MONTAG
Siemens Healthineers

ANDREAS PENK
Pfizer Germany

HAGEN PFUNDNER
Roche Pharma AG

PETER PIOT
London School of Hygiene and Tropical Medicine

ERICH REINHARDT
Medical Valley

HEINZ RIEDERER

MAIKE RÖTTGER
Association Development and Humanitarian Aid

MATHIAS SCHELLER
Albertinen-Diakoniewerk

HANS J. SCHELLNHUBER
Potsdam Institute for Climate Impact Research

GEORG SCHÜTTE
German Federal Ministry of Education and Research

GÜNTER STOCK
ALLEA All European Academies

LOTTHAR WIETER
Robert Koch Institute

(* to be confirmed)
The M8 Alliance’s vision is to harness academic excellence to improve global health.

The M8 Alliance of Academic Health Centres, Universities and National Academies is a collaboration between academic institutions committed to improving global health. Working together with political and economic decision-makers, its primary goal is to develop science-based solutions to health challenges all over the world.

This international network is the outstanding academic foundation upon which the World Health Summit – the pre-eminent annual forum for healthcare dialogue – is built. It functions as a permanent platform for framing the future considerations of global medical developments and health challenges in an equitable fashion.

The M8 Alliance promotes both “bench-to-bedside” translation of research and the transformation of current medical care approaches to treating the ill. It is seeking to accomplish this through the creation of a healthcare system focused on the effective prevention of diseases, as well as the adaptation of health-related solutions to rapidly changing living conditions through research in priority areas like shifting demographics, urbanization and climate.
Tehran University of Medical Sciences (TUMS) is accredited with premier status by the Accreditation Service for International Colleges (ASIC). ASIC is recognized by the United Kingdom Department for Education and Skills (DfES), the United Kingdom Department for Universities, Innovation and Skills (DUIS), the United Kingdom Border and Immigration Agency (Home Office), the United Kingdom Office for Standards in Education (Ofsted). ASIC is a member of Council for Higher Education Accreditation (CHEA).
The M8 Alliance is improving global health through pursuit of five strategic goals:

- Developing a worldwide network of academic health science centers, and bringing together universities and healthcare providers;

- Facilitating dialogue through the World Health Summit across a global network of stakeholders who are engaged with academic health science centers. These stakeholders include (among others) individuals and institutions active in government, industry and commerce, inter-governmental agencies, healthcare providers, academies of medicine and science, professional associations and the media;

- Setting an agenda for global health improvement by addressing issues of interest to academic health science centers, and conveying findings and recommendations based on scientific evidence through the generation of key statements;

- Positioning the M8 Alliance as an authoritative, credible and respected influence when it comes to decision-making in global health; and

- Creating a knowledge base amongst M8 Alliance members, which directly involves the promotion of mutual learning, research collaboration, the enrichment of educational capabilities and enhanced clinical outcomes.
EXECUTIVE COMMITTEE

HÉLÈNE BOISJOLY
Acting International President
Dean, Faculty of Medicine, University of Montreal, Canada

DETLEV GANTEN
Founding President
Honorary Chairman of the Board, Charité Foundation, Germany

JOÃO GABRIEL SILVA
Incoming International President
Rector, University of Coimbra, Portugal

ANTOINE FLAHAULT
Past International President
Director, Institute of Global Health, University of Geneva, Switzerland

AXEL RADLACH PRIES
Dean of Host Institution
Charité – Universitätsmedizin Berlin, Germany

MICHAEL J. KLAG
Strategic Co-operation and Stakeholder Liaison
Former Dean, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

BEN CANNY
Governance and Fundraising
Head, School of Medicine, University of Tasmania, Australia

JOSÉ OTÁVIO AULER JR.
Officer at large
Dean, Faculty of Medicine, University of São Paulo, Brazil
# M8 ALLIANCE HEADS OF DELEGATION

<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
<th>Position/Title</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>CHRISTINA MITCHELL</td>
<td>Dean</td>
<td>Monash University, Melbourne</td>
</tr>
<tr>
<td>Brazil</td>
<td>JOSÉ OTÁVIO AULER JR.</td>
<td>Dean</td>
<td>Dean, Faculty of Medicine, University of São Paulo</td>
</tr>
<tr>
<td></td>
<td>EDUARDO KRIEGER</td>
<td>Former President</td>
<td>Brazilian Academy of Sciences</td>
</tr>
<tr>
<td>Canada</td>
<td>HÉLÈNE BOISJOLY</td>
<td>Dean</td>
<td>Faculty of Medicine, University of Montreal</td>
</tr>
<tr>
<td></td>
<td>TARIK MÖRÖY</td>
<td>President</td>
<td>Clinical Research Institute Montreal (IRCM)</td>
</tr>
<tr>
<td>China</td>
<td>XUETAO CAO</td>
<td>President</td>
<td>Chinese Academy of Medical Sciences &amp;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Peking Union Medical College</td>
</tr>
<tr>
<td></td>
<td>DEPEI LIU</td>
<td>Co-Chair</td>
<td>InterAcademy Partnership (IAP) for Health</td>
</tr>
<tr>
<td>France</td>
<td>GÉRARD FRIEDLANDER</td>
<td>Dean</td>
<td>Faculty of Medicine, University of Paris Descartes</td>
</tr>
<tr>
<td></td>
<td>FRANÇOIS HOULLIER</td>
<td>Acting President</td>
<td>Université Sorbonne Paris Cité</td>
</tr>
<tr>
<td>Germany</td>
<td>KARL MAX EINHÄUPL</td>
<td>Chief Executive Officer</td>
<td>Charité - Universitätsmedizin Berlin</td>
</tr>
<tr>
<td></td>
<td>AXEL RADLACH PRIES</td>
<td>Dean</td>
<td>Charité - Universitätsmedizin Berlin</td>
</tr>
<tr>
<td>Japan</td>
<td>SHUNICHI FUKUHARA</td>
<td>Dean</td>
<td>School of Public Health, Kyoto University</td>
</tr>
<tr>
<td>Portugal</td>
<td>FERNANDO REGATEIRO</td>
<td>Chairman of the Board of Directors</td>
<td>Coimbra University Hospitals</td>
</tr>
<tr>
<td></td>
<td>JOÃO GABRIEL SILVA</td>
<td>Rector</td>
<td>University of Coimbra</td>
</tr>
<tr>
<td>Russian Federation</td>
<td>IVAN DEDOV</td>
<td>President</td>
<td>Russian Academy of Medical Sciences</td>
</tr>
<tr>
<td></td>
<td>EVGENY SIDORENKO</td>
<td>Vice-President</td>
<td>Russian Academy of Medical Sciences</td>
</tr>
<tr>
<td>Singapore</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>JOHN EU-LI WONG</strong></td>
<td><strong>CHANG-CHUAN CHAN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td>Associate Dean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National University Health System</td>
<td>National Taiwan University</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Senior Vice-President (Health Affairs), National University of Singapore</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>KHAY GUAN YEOH</strong></td>
<td><strong>MAHMUT AK</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dean</td>
<td>Rector</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yong Loo Lin School of Medicine, National University of Singapore</td>
<td>Istanbul University</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Switzerland</strong></td>
<td><strong>BAHAÜDDIN ÇOLAKOGLU</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HENRI BOUNAMEAUX</strong></td>
<td>Dean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dean</td>
<td>Istanbul University, Faculty of Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ANTOINE FLAHAULT</strong></td>
<td><strong>NELSON K. SEWANKAMBO</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director</td>
<td>Principal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Institute of Global Health</td>
<td>Makerere University</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ILONA KICKBUSCH</strong></td>
<td><strong>United Kingdom</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director</td>
<td><strong>PETER PIOT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Faculty of Medicine, University of Geneva</td>
<td>Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BERTRAND LEVRAT</strong></td>
<td><strong>London School of Hygiene &amp; Tropical Medicine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geneva University Hospitals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLAUDINE MATHIEU-THIÉBAUD</strong></td>
<td><strong>ELIO RIBOLI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director</td>
<td>Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National and International Affairs, Geneva University Hospitals</td>
<td>School of Public Health, Imperial College London</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>USA</strong></td>
<td><strong>LEONEL VALDIVIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ELLEN MACKENZIE</strong></td>
<td>Dean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dean</td>
<td>Johns Hopkins Bloomberg</td>
<td>School of Public Health, Baltimore</td>
<td></td>
</tr>
<tr>
<td><strong>MICHAEL J. KLAG</strong></td>
<td><strong>International</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former Dean</td>
<td><strong>STEVEN A. WARTMAN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins Bloomberg</td>
<td>President &amp; Chief Executive Officer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>School of Public Health,</td>
<td>Association of Academic Health Centers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baltimore</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Uganda</strong></td>
<td><strong>Individual Members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NELSON K. SEWANKAMBO</strong></td>
<td><strong>RIFAT ATUN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal</td>
<td>Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Makerere University</td>
<td>Global Health Systems Cluster, Harvard T.H. Chan School of Public Health, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>United Kingdom</strong></td>
<td><strong>BEN CANNY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PETER PIOT</strong></td>
<td>Head</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ELIO RIBOLI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Director</strong></td>
<td>School of Medicine, University of Tasmania, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Director</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>School of Public Health, Imperial College London</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
WELCOME TO THE
WORLD HEALTH SUMMIT
BERLIN 2017
Held under the high patronage of:

**Hermann Gröhe**
Federal Minister of Health
Germany

The World Health Summit Startup Track highlights outstanding ideas and innovative business concepts that have the potential to revolutionize healthcare and improve global health.

70 applications from 23 countries were assessed by the jury to select the 25 shortlisted organizations, which were subsequently invited to the World Health Summit 2017. Of these, 10 finalists will pitch their ideas in front of the audience and jury on Monday, October 16.

The winner will be awarded by German Federal Minister of Health Hermann Gröhe at the World Health Summit Night.

**Benefits**
- Awarded by the German Minister of Health
- Special access to the World Health Summit and M8 Alliance network
- Exclusive coaching from FLYING HEALTH, one of the leading company builders for health startups in Germany

**Pitch**
Monday, October 16, 12:45
Saal 1 | Rudolf Virchow

**Award**
Monday, October 16, 18:30
Saal 1 | Rudolf Virchow

The winner will be awarded by Minister of Health Hermann Gröhe.

**Jury**

- **KAI-UWE BINDSEIL**
  Berlin Partner for Business and Technology

- **JUTTA KLAUER**
  Pfizer Germany

- **SHARI LANGEMAK**
  Philips

- **MARKUS MÜSCHENICH**
  Flying Health

- **ANNE KJAER RIECHERT**
  ReDI School of Digital Integration

- **RENAE RADON**
  Microsoft Germany

- **OLIVER SCHENK**
  German Ministry of Health

- **UTE E. WEILAND**
  Deutschland – Land der Ideen
THE 10 FINALISTS

**AMBOSS | Germany**  
Business Area: Education  
www.amboss.com

**Amparo GmbH | Germany**  
Business Area: Assistive Devices  
www.amparo.world

**CareNX Innovations | India**  
Business Area: Maternal and Child Health  
www.carenx.com

**doctHERs | Pakistan**  
Business Area: Digital Health  
www.doctthers.com

**Fosanis GmbH | Germany**  
Business Area: Cancer Care  
www.fosanis.de

**imoto AG | Switzerland**  
Business Area: Visual Documentation  
www.imito.io

**monikit UG | Germany**  
Business Area: Epilepsy  
www.monikit.com

**PharmaChk | USA**  
Business Area: Quality Detection  
www.pharmachk.com

**SciDogma Research | India**  
Business Area: Diagnostics  
www.scidogma.com

**WeCare.id | Indonesia**  
Business Area: Healthcare Financing  
www.wecare.id

www.worldhealthsummit.org/whs-2017/startup-track
Monday, October 16, 18:30  
Saal 1 | Rudolf Virchow  
The World Health Summit Night as the central networking event hosts the award ceremony of the Startup Track.
The New Voices in Global Health initiative promotes the active participation of young scientists in the World Health Summit. It is supported by the M8 Alliance of Academic Health Centers, Universities and National Academies. It is aimed at empowering research, policy and advocacy initiatives among future leaders in global health, who are invited to send in abstracts of their scientific work and ideas. The World Health Summit Scientific Committee (see page 21) identified the best applications based on international academic standards. The selected candidates will be able to display their work in a special poster exhibition, thus playing an active role in the World Health Summit.

The selected New Voices in Global Health are:

**Kiarash Shirbandi**
Ahvaz Jundishapur University of Medical Sciences, Iran
“Global View of HIV Prevalence in Prisons: A Systematic Review and Meta-Analysis”

**Luz Upegui**
RWTH Aachen University, Germany
“Antimicrobial Resistance: Knowledge Towards Antibiotics in a Mexican Population”

**Anne Musuva**
Population Services Kenya
“The Kenyan Malaria Market after the Affordable Medicines Facility for Malaria”

**Shubha Nagesh**
Latika Roy Foundation, India
“Community Health Workers in Early Intervention for Children with Special Needs in the Uttarakhand Himalayas”

October 15–17, 2017, 09:00–18:00
In front of Saal 7 | Elizabeth Blackwell
Faith Nawagi
Global Educational Exchanges in the Medicines and the Health Professions, a service of ECFMG, Uganda
“Regional Networks: An Approach to Enhance Global Health Exposure for Medical and Health Professional Students in Africa”

Nakazinga Ndugwa
University of Queensland, Australia
“Exploring the Health Systems Requirements for Scaling up Care for Psychosocial Early Childhood Development in Uganda”

Derick Niyonshima
Makerere University, Uganda
“Determination of Staphylococcus Aureus Contamination of Liquid Local Herbal Medicine Sold in Kampala City, Uganda”

M Tasdik Hasan
International Center for Diarrheal Diseases Research, Bangladesh
“Exploring Mental Health Services Among Climate Victims in a Cyclone Affected Area of Coastal Bangladesh”

Surendra Karki
UNSW, Australia
“Association Between Body Mass Index and Laboratory-confirmed Influenza in Middle-aged and Older Adults: A Prospective Cohort Study”

Solomon Abiola
University of Rochester Medical Center, USA
“Real-Time Geospatial Forecasting of Infectious Diseases Using mHealth app ‘Node’, Lagos, Nigeria 2015 Ebola Case Study”
PROGRAM

SUNDAY, OCTOBER 15
PANEL DISCUSSION

HEALTHY AND RESILIENT CITIES
Rethinking Urban Transformation

HOSTS
Joint United Nations Programme on HIV/AIDS (UNAIDS)
M8 Alliance:
Tehran University of Medical Sciences
The Graduate Institute of International and Development Studies

Two transformative agendas come together at the city level—the new urban agenda and implementation of the sustainable development goals. Many global health actors have recognized that cities play an increasingly important role in ensuring health and well-being and responding to chronic stresses and acute shocks. A central question is how we can best achieve urban resilience, so that individuals, communities, institutions, businesses, and systems within a city are motivated to survive, adapt, and grow.
CHAIR

Ilona Kickbusch
The Graduate Institute of International and Development Studies | Global Health Center | Director | Switzerland

SPEAKERS

Anna Dworakowska
Polish Smog Alert | Co-Founder | Poland
What Difference can Innovative Citizen Action on Urban Health Make

Ali Jafarian
Tehran University of Medical Sciences | Chancellor | Iran
The Universities Role in Addressing Urbanization and Noncommunicable Risk Factors

Matshidiso Rebecca Moeti
World Health Organization (WHO) | WHO Regional Office for Africa | Regional Director for Africa | Congo
How can the WHO Support Cities in Addressing the Negative Health Impact of Rapid Urbanization in Africa

Mohammed Adjei Sowah
Mayor of Accra | Ghana
What Role can Mayors Play in Initiating Action on NCDs

José Zuniga
Joint United Nations Programme on HIV/AIDS (UNAIDS) | Special Adviser on Fast-Track Cities | Switzerland
Fast Track Cities in Ending the AIDS Epidemic

Ilona Kickbusch

José Zuniga

Mohammed Adjei Sowah

Ali Jafarian

Anna Dworakowska

Matshidiso Rebecca Moeti
WORKSHOP

GENDER EQUALITY WITHIN THE GLOBAL HEALTH WORKFORCE

Working for a new Status Quo

HOSTS

M8 Alliance:
Monash University
Women in Global Health

This workshop will examine the global health workforce with a gender lens and will focus on the interplay between gender equal leadership and the advancement of health globally. We hope to address questions in this workshop such as: What barriers do different personnel in the global health workforce face and how do institutions, governments, NGOs, the private sector and individuals help to remove those barriers? How do we combine SDG 3 on health, and SDG 5 on gender equality to develop a strong gender equal global health leadership at all levels?

An introductory panel will explore both barriers and successes that women have faced both in leadership and throughout their careers, with a focus on political life, academia, private sector and health workforce. The panel will provide a brief introduction to the topic to provide food for thought for the second half of the session. Following the panel, attendees will be invited to join smaller breakout groups where they will be guided through a case study and a series of thought provoking discussion questions which enable them to delve deeper into the questions outlined above.

The breakout sessions will conclude with a brief recap and introduction to a gender mainstreaming tool that attendees can utilize in their own work. Each group will be provided with the opportunity to briefly report back on their discussions. This will be an interactive workshop, where group discussion based on case studies and tools will be held after the introductory panel.
CHAIR

Sally Theobald
Liverpool School of Tropical Medicine (LSTM) | Chair, Social Science and International Health | United Kingdom

SPEAKERS

Heidemarie Wieczorek-Zeul
Friends of the Global Fund Europe | Vice President | Germany
Women in Global Health
Political Leadership

Jan Coles
Monash University | Medicine, Nursing and Health Sciences | Director of Research | Australia
Challenges for Leadership in Gender Based Violence Education for Health Professionals

Roopa Dhatt
Women in Global Health | Initiative Director & Co-Founder | United States of America
Current Status of Women in Global Health Leadership

Olawunmi Oduyebo
All Things Health Africa (ATHA) | Founder | Kenya
Women Leading the Way in Tech and the Private Sector

Charlotte Rees-Sidhu
Monash University | Centre for Scholarship in Health Education | Director | Australia
Women’s Experiences in Medical Education

Sonia Singh
PwC Strategy& | Senior Director | United States of America

Sharyn Tenn
International Partnership for Microbicides (IPM) | Senior Director of External Affairs | United States of America
Challenges for Leadership in Gender Based Violence Education for Health Professionals

Kelly Thompson
Women in Global Health | Gender Specialist | United States of America

Topic Case Study - WHO Executive Board

Sreytouch Vong
Cambodia Development Resource Institute | Cambodia
Barriers and Discrimination by Gender in the Cambodian Health Workforce

Tana Wuliji
World Health Organization (WHO) | Technical Officer, Health Workforce | Switzerland
Barriers and Discrimination by Gender in the Global Health Workforce
The number and type of infectious disease outbreaks have increased significantly over the past 30 years. As global trade and travel enable humans and goods to be more and more mobile, the risk of diseases spreading beyond national borders increases. Infectious diseases are often mistakenly viewed as mere health issues. However, they are potentially grave threats to countries’ security as well as economic and human development.

Given that pandemics can devastate economies and threaten both development and major investments by multinationals and small businesses alike, the public and the private sector share interests in ensuring that global epidemics, such as Ebola, are quickly recognized and contained and that global endemics, such as HIV and Zika, are sustainably addressed through health systems.

In this session, we will discuss interventions and health systems improvements to better prepare countries and the global community for the epidemics and endemics of the future.
**CHAIR**

Till Bärnighausen  
Heidelberg Institute of Public Health (HIPH) | Director | Germany

**SPEAKERS**

Raymonde Goudou Coffie  
Ministry of Health and Public Hygiene | Minister | Ivory Coast

Christian Drosten  
Charité – Universitätsmedizin Berlin | Institute of Virology Campus | Charité Mitte | Director | Germany

Trevor Mundel  
Bill & Melinda Gates Foundation | President of the Global Health Division | United States of America

Harald Nusser  
Novartis | Head, Novartis Social Business | Germany

Lothar H. Wieler  
Robert Koch Institute | President | Germany
Cancer is one of the fastest growing noncommunicable diseases (NCDs). A coordinated global effort between patients, the biopharmaceutical industry, government and civil society is urgently needed to address the full range of barriers to treatment and care, and increase the availability of affordable cancer care and access to essential medicines.

But with so many different barriers and needs to address, how are these multisectoral collaborations created and what considerations need to be taken into account for these partnerships to be impactful? True collaboration requires buy in from all stakeholders, and a decision making process that weighs a diverse set of needs and balances them with the best interests of patients.

This panel will explore the lessons learned and success factors that communities across the world need to be aware of to form partnerships that make significant progress in reducing premature deaths from NCDs. Speakers from the government, industry, NGOs and patient advocacy organizations will participate to share their perspectives.
CHAIR

Shiulie Ghosh
TRT World | Journalist | Turkey

SPEAKERS

HRH Princess Dina Mired of Jordan
Union for International Cancer Control (UICC) | President-Elect | Switzerland
Overcoming Obstacles for Cancer Treatment and Care: Collaboration and the Role of NGOs

Michael Baumann
German Cancer Research Center | Chairman & Scientific Member of the Management Board | Germany
Can Research Institutions Impact Health Care on a Global Level? – Example Cancer Research

Joseph Kibachio
Ministry of Health | Division of Noncommunicable Diseases | Head | Kenya
The Role of Government: Addressing Local Challenges with Local Solutions

Andrew Spiegel
International Alliance of Patients’ Organizations | Member of the Governing Board | United Kingdom
The Role of Patient Groups and Patients in Influencing Management of Care

Thomas B. Cueni
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director General | Switzerland
The Role of Industry: The Example of the Access Accelerated Initiative
The European Commission’s Scientific Panel for Health (SPH) is a science-led expert group based on the provisions of the Horizon 2020 Specific Programme that has been tasked with helping to achieve better health and wellbeing for all. Although, health and disease know no borders, health research is often limited by national boundaries, resources and priorities. Strategic health research programmes and international research collaborations have shown success in responding to health priorities, especially in crisis situations.

A healthier research ecosystem – open, collaborative, innovative – could continually deliver solutions for improved health. To further health research across the EU, the SPH is leading a proposal for comprehensive policy for health research, encompassing broad stakeholder participation. This WHS workshop offers an opportunity to engage with world leaders in health research to discuss the potential for European health research to build on its global outreach and collaboration.
CHAIR

Karin R. Sipido
European Commission | Scientific Panel for Health | Chair | Belgium

SPEAKERS

Elizabeth Blackburn
Salk Institute for Biological Studies | President | United States of America

Depei Liu
Chinese Academy of Engineering | Former Vice President & President of InterAcademy Partnership (IAP) for Health | China

Elmar Nimmesgern
European Commission | Deputy Head of Unit Innovative and Personalised Medicine | Belgium

Otmar D. Wiestler
Helmholtz Association of German Research Centers e.V. | President | Germany

DISCUSSANTS

Rupert Gerzer
Skoltech Center for Translational Biomedicine | Provost | Russia

Karin R. Sipido
European Commission | Scientific Panel for Health | Chair | Belgium

Elizabeth Blackburn
Salk Institute for Biological Studies | President | United States of America

Depei Liu
Chinese Academy of Engineering | Former Vice President & President of InterAcademy Partnership (IAP) for Health | China

Elmar Nimmesgern
European Commission | Deputy Head of Unit Innovative and Personalised Medicine | Belgium

Otmar D. Wiestler
Helmholtz Association of German Research Centers e.V. | President | Germany
Between 2000 and 2050, the proportion of the world’s population aged 60 years or over will double from about 11% to 22%. By 2050, Europe will have about 34% of its population aged 60 years or over.

In 2000, Japan implemented Long-Term Care (LTC) policy with a new public insurance system for LTC. In 2016, Taiwan has started a second ten-year LTC Plan aiming to coordinate LTC services and develop a continuum of care system. We will share the current status of LTC policy in Japan and Taiwan and a framework of investigating the mechanism of integrated LTC service through our collaboration between the NTU and KU.

In WHO’s 2016 report, autonomy, including advanced care planning, has been repeatedly identified by older adults as a core component of their wellbeing. Taiwan’s Patient Self-Determination Act was legalized in 2016 and will take effect in 2019. Patients can make their own Advance Directive via Advanced Care Planning (ACP) by stating whether they wish to accept or refuse life-sustaining treatments.

Facing the challenge as ones of the fastest aging counties in the world, Kyoto University (KU) and National Taiwan University (NTU) are now collaborating on the first Action Initiative project approved by the World Health Summit.
CHAIRS

Chang-Chuan Chan  
National Taiwan University (NTU) |  
Dean, College of Public Health | Taiwan

Shunichi Fukuhara  
Kyoto University | Dean, School of Public Health | Japan

Fernando Regateiro  
Coimbra University Hospitals |  
Chairman of the Board of Directors | Portugal

SPEAKERS

Shunichi Fukuhara  
Kyoto University | Dean, School of Public Health | Japan  
Overview and Progress of Action Initiative Project on Long-Term and End-of Life Care in Aging Societies

Ya-mei Chen  
National Taiwan University (NTU) |  
Deputy Director, College of Public Health | Taiwan  
The Framework of Investigating the Mechanism of Integrated Long-Term Care Service

Kai-Uwe Eckardt  
Charité - Universitätsmedizin Berlin |  
Director, Division of Nephrology and Internal Intensive Care Medicine | Germany  
Chronic Kidney Disease – A Challenge for Ageing Populations

Chih-Yuan Shih  
National Taiwan University (NTU) |  
Director of Health Promotion and Management Center | Taiwan  
Impact of Advanced Care Planning policy on End of Life Care in Taiwan

Yvette Lajeunesse  
University of Montreal | Professor | Canada  
The New Challenges of End of Life Medical Care in Québec
As the leading cause of death and disability worldwide, noncommunicable diseases (NCDs) are now widely recognized as a major challenge to health and sustainable human development in the 21st century. Half of those who die of NCDs are in the prime of their productive years, and thus, the disability imposed and the lives lost are adversely affecting communities, businesses and governments through losses in macroeconomic productivity, national income, healthcare budgets and household income.

While the economic and social burden of NCDs is immense, the financial investment to alleviate this burden on patients, families and carers is comparatively small. Immediate actions to reduce the burden caused by NCDs include action to address the main risk factors (tobacco use, harmful use of alcohol, unhealthy diets, and physical inactivity), and strengthening health systems to better respond to NCDs. Many of the interventions recommended by the WHO, the so-called ‘best buys for NCDs’, are very cost-effective even for LMICs, with price tags as low as 0.20 USD per capita/year for population-based policies and other measures.

Despite previous high-level commitments to strengthen national NCD responses and evidence-based recommendations for cost-effective action, progress at national levels remains insufficient and uneven. At the current pace, countries will not achieve the global ‘25 by 25’ NCD goal. In view of the upcoming 2018 UN High-Level Meeting on NCDs, there is a need to address common barriers and bottlenecks and explore common success factors and catalytic strategies applicable to different economic settings to support the implementation of effective NCD prevention policies and sustainable health systems for NCDs globally.
CHAIR

Andrew Jack
Financial Times | Editor | United Kingdom

SPEAKERS

HRH Princess Dina Mired of Jordan
Union for International Cancer Control (UICC) | President-Elect | Switzerland
Introductory Keynote

Katie Dain
The NCD Alliance | CEO | United Kingdom

Gauden Galea
WHO Regional Office for Europe | Division of Noncommunicable Diseases and Health Promotion | Director | Denmark

Joseph Kibachio
Ministry of Health | Division of Noncommunicable Diseases | Head | Kenya

Stefan Oelrich
Sanofi | Head Global Diabetes Franchise | Senior Vice President | Germany

Rajitha Senaratne
Ministry of Health, Nutrition and Indigenous Medicine | Minister | Sri Lanka

HRH Princess Dina Mired of Jordan

Katie Dain

Gauden Galea

Stefan Oelrich

Andrew Jack

Rajitha Senaratne

Joseph Kibachio
The US withdrawal from the Paris Agreement came as a shock, and could have worrying environmental consequences, but not only.

Climate change is indeed central to all the major challenges of the 21st century: the rising temperature, extreme weather events and greenhouse gas emission have direct or indirect effects on food security, urban policies, or even migration. As well, climate change poses an important threat to our health. However, tackling climate change could represent “the greatest global health opportunity of the 21st century”.

This session will explore the health impacts of climate change as foreseen since the 2015 Paris Agreement. Three main topics will be addressed: Health as an argument in the climate change negotiations; Climate change, migration and health; Climate change, food security and health.
CHAIRS

Anneliese Depoux
Centre Virchow-Villermé for Public Health Paris-Berlin | Co-Director | France

Jörg Hacker
German National Academy of Sciences Leopoldina e.V. | President | Germany

SPEAKERS

Antoine Flahault
University of Geneva | Institute of Global Health | Director | Switzerland
Climate Change and Emerging Infectious Diseases

François Houllier
Université Sorbonne Paris Cité | President | France
Climate Change and Food Security

Corinne Kowalski
Centre Virchow-Villermé for Public Health Paris-Berlin | International Affairs Manager | France
Health as an Argument in the Climate Negotiations

Joacim Rocklöv
Lancet Countdown | Umeå University | Associate Professor in Epidemiology | Sweden
Lancet Countdown: Tracking Progress on Health and Climate Change

Muhammad H. Zaman
Boston University | Professor of Biomedical Engineering | United States of America
Climate Migration and Health
WORKSHOP

ARTIFICIAL INTELLIGENCE IN HEALTH
The Beginning of a Primary Care Revolution

HOST
Fondation Botnar

This session will present the views of leading change-makers in Artificial Intelligence (AI) that offer solutions for transforming health access, information and diagnostics for the wellbeing of children.

The session will set out to:

1) identify avenues for achieving the vision of universal free access to quality health information and diagnostics powered by AI, and
2) demonstrate concrete examples including a short demonstration of “AI and rare diseases” through practical examples.

Questions that will be tackled:

• How can AI ensure healthy lives and promote well-being for all children by 2030?
• How can AI transform and revolutionize access, information and diagnostics through a multi-stakeholder approach of tech giants, startups, investors, researchers, and developers from every corner of the AI ecosystem?
• What do these solutions look like and how can they be implemented and scaled?
• What are critical issues for planning and implementing such solutions?
CHAIR

Stefan Germann
Fondation Botnar | CEO | Switzerland

SPEAKERS

Sabine Gless
Faculty of Law of Basel University | Criminal Law and Criminal Procedure | Professor | Switzerland
Legal and Ethics in Artificial Intelligence

Martin Hirsch
Ada Health | Founder and Chief Scientific Officer | Germany
Health Diagnostics

Arthur Kaindl
Siemens Healthcare | Digital Health Services | General Manager | Germany
Health Digitalization

Hassan Mshinda
Tanzania Commission for Science and Technology (COSTECH) | Director General | Tanzania
Innovation, Digital Applications and Public-Private Partnerships for Sustainable Development in Tanzania
In 2010 the EU Foreign Affairs Council adopted the EU Council Conclusions on Global Health. It took as its starting point a commitment to equity and Health in all policies and provided a framework for EU input regarding SDG cooperation. It was based upon an intersectoral Commission Communique. Now that the Agenda 2030 has been adopted it is time to revisit the EU’s role in global health. The global environment has changed significantly and new priority issues and key actors have emerged.

In July 2017 the EU adopted its new development consensus, which includes references to the SDG health goals. The biggest challenge however will be how other EU policies and investments – trade, research, foreign affairs, agriculture etc., will contribute to the determinants of global health and policy coherence for SDG achievement. This workshop will aim to identify strategic steps to reinvigorate the EU’s role in global health.
CHAIR

Eero Lahtinen
Permanent Mission of Finland in Geneva | Counsellor | Switzerland

SPEAKERS

Thea Emmerling
Delegation of the European Union to the United States | Health, Food Safety, and Consumer Affairs Section | Minister Counselor | United States of America
The 2010 Commission Communication and 2011 Council Conclusion on the EU role in Global Health: What did we Decide? What have we Achieved?

Björn Kümmel
Bundesministerium für Gesundheit / Federal Ministry of Health (BMG) | Deputy Head of Division Global Health | Germany
Challenges and Perspectives for a Stronger Role of the EU in Global Health – Practical Experiences from the WHO

Robert Madelin
Fipra International | Chairman | Belgium
Global Health Futures: Making Europe a Positive Player

Martin McKee
London School of Hygiene and Tropical Medicine (LSHTM) | Professor of European Public Health | United Kingdom
Global Health: If not Europe, who? If not now, when?
In October 2016, a collaborative community of world-leading scientists met in London, and discussed how to build a Human Cell Atlas—a collection of maps that will describe and define the cellular basis of health and disease.

Cells are the most fundamental unit of life, yet we know surprisingly little about them. They vary enormously within the body, and express different sets of genes. Without maps of different cell types and where they are located in the body, we cannot describe all their functions and understand the biological networks that direct their activities.

A complete Human Cell Atlas would give us a unique ID card for each cell type, a three-dimensional map of how cell types work together to form tissues, knowledge of how all body systems are connected and insights into how changes in the map influence health and disease. It would allow us to identify which genes associated with disease are active in our bodies and where, and analyze the regulatory mechanisms that govern the production of different cell types.

This has been a key challenge in biology for more than 150 years. New tools such as single-cell genomics have put it within reach. It is an ambitious but achievable goal, and requires an international community of biologists, clinicians, technologists, physicists, computational scientists, software engineers and mathematicians.
CHAIRS

Martin J. Lohse
Max Delbrück Center for Molecular Medicine | Chair of the Board of Directors and Scientific Director | Germany

Nikolaus Rajewsky
Max Delbrück Center for Molecular Medicine | Systems Biology of Gene Regulatory Elements | Head of the Group | Germany

SPEAKERS

Joachim L. Schultze
University of Bonn | Genomics & Immunoregulation, LIMES-Institut | Department Head | Germany

Fabian Theis
Helmholtz Zentrum Munich | Group Leader Machine Learning | Head of Institute | Germany

Jörg Vogel
University of Würzburg | Institute for Molecular Infection Biology | Director | Germany
The concept and practice of precision medicine took center-stage during the 2015 State of the Union address by U.S. President Barack Obama, when he proclaimed the goal of funding a national “precision medicine initiative.” The stated mission of this initiative was clear: “to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized treatments.” The goal of precision medicine is therefore to approach disease treatment and prevention by taking into account the individual variability in environment, lifestyle and genes for each person.

This announcement and approach has led to a variety of responses, from enthusiastic expectation to explicit skepticism about potential health benefits, limitations, and return on investment. Will the precision medicine approach become a valuable ally in improving population health or will its effects be negligible?

The session specifically aims to see whether a consensus can be forged between these disparate perspectives on this contentious issue.
CHAIR

Martin J. Lohse
Max Delbrück Center for Molecular Medicine | Chair of the Board of Directors and Scientific Director | Germany

SPEAKERS

Elizabeth Blackburn
Salk Institute for Biological Studies | President | United States of America

Elena Bonfiglioli
Microsoft Corporation | Senior Director Health Industry, Europe Middle East Africa (EMEA) | United States of America

Erwin Paul Böttinger
University of Potsdam | Digital-Engineering Faculty | Specialist for Digital Health | Germany

Tarik Möröy
Montreal Clinical Research Institute (IRCM) | President and Scientific Director | Canada

Andreas Radbruch
German Center for Research of Rheumatism (DRFZ) | Scientific Director | Germany
The arrival of migrants from different cultures has been and continues to be a major challenge to healthcare systems in receiving countries. In particular, healthcare providers in those countries have to take into account in their daily work questions of diversity and identity in relation to their own cultural practices. This can also lead to a clash of values not least in relation to gender. Questions of perception and attitudes from both sides represent a particular challenge within the framework of globalization. This workshop aims at a taking stock of different experiments in different regions and countries having had to deal with the integration of substantial numbers of migrants. A global comparison might lead to practical conclusions for public health policies.
CHAIRS

Johanna Hanefeld
London School of Hygiene & Tropical Medicine (LSHTM) | Associate Professor of Health Policy and Systems | United Kingdom

H.E. Reinhard Schäfers
World Health Summit | Ambassador | Germany

SPEAKERS

Giannis Baskozos
Ministry of Health | Public Health | Secretary General | Greece
The Immunization in Migration and Global Health Policy

Walter Ricciardi
National Institute of Health | President | Italy
Migrants and Health: An Italian Perspective

Joachim Seybold
Charité – Universitätsmedizin Berlin | Deputy Medical Director | Germany
Health Care for Refugees in Berlin: Challenges and New Concepts

Heidi Stöckl
London School of Hygiene & Tropical Medicine (LSHTM) | Associate | United Kingdom
Mobile Populations, Violence and Health

DISCUSSANTS

Luciano Saso
Sapienza University of Rome | Faculty of Pharmacy and Medicine | Vice-Rector for European University Networks | Italy

Ahmad Tarakji
Syrian American Medical Society | President | United States of America
This session is based upon the experiences and recommendations of an international expert group which published a unique report regarding the state of oncology within the African continent. It is impossible to avoid the conclusion that there is an urgent need for major coordinated actions with Public-Private Partnerships to make necessary progress. The session will reflect on the call to action which was issued by the authors and how to best pursue this within the fastest possible time frame, taking into account all stakeholders involved.
**CHAIRS**

*Manfred Dietel*
Charité – Universitätsmedizin Berlin | Institute for Pathology | Director | Germany

*Andreas Penk*
Pfizer Germany | Oncology International Developed Markets | Regional President | Germany

**SPEAKERS**

*Peter Boyle*
International Prevention Research Institute (iPRI) | President | France

*Markus Kosch*
Pfizer Pharma | Oncology Portfolio, Europe, Japan & Developed Asia | Vice President | Germany

*Twalib Ngoma*
Open Road Cancer Institute (ORCI) | Executive Director | Tanzania
The aim of this workshop is to identify how political stakeholders should respond to the issue of supply shortages of essential medicines, an issue affecting both developing and developed countries today. Despite the pharmaceutical industry, research and development being globally interwoven, availability of essential medicines remains a key issue.

Policy responses require concerted action and coordinated approaches. In line with SDG 3, governments have committed to health and wellbeing as a universal objective, ensuring access for all individuals to safe, effective and affordable medicines.

Several initiatives including the ‘Lancet Commission on Access to Medicines’ and a high level panel endorsed by the UN Secretary General have analyzed gaps and possible solutions forward in existing responses.

The latest UN Report on Access to Medicine regarding conclusions on joint priority actions will be presented. The ensuing discussion will focus on expectations regarding the Fair Prices Forum, provision of resources, global and local regulation and implementation, as well as possibilities for follow up actions.
CHAIR

Susanne Weber-Mosdorf
World Health Organization (WHO) | Former Assistant Director General | Germany

SPEAKERS

Ruth Dreifuss
The United Nations Secretary-General’s High-Level Panel on Access to Medicines | Co-Chair | Switzerland
Introductory Keynote:
The Way Forward – Conclusions from The United Nations Secretary-General’s High-Level Panel on Access to Medicines Report

Franz Knieps
BKK Governing Body | Member of the Board | Germany

Rüdiger Krech
World Health Organization (WHO) | Office of the Assistant Director-General | Health Systems and Innovation | Director | Switzerland

Suerie Moon
Graduate Institute of International and Development Studies | Director of Research, Global Health Centre and Visiting Lecturer | Switzerland
Progress and dementia poses a paradox: providing growing insights into pathophysiology but not a single disease modifying drug. The current reductionist approach needs to be complemented by an understanding of complex systems and the most powerful determinant of cognitive impairment, namely aging.

Most of our understanding of dementia derives from studies of Western populations that may differ from other populations, not only culturally but genetically and biologically. Dementia, although a global problem, manifests differently in different parts of the world.

The Global World Council does recognize this and as the highest coordinating body in the fight against dementia, encompasses a diverse, comprehensive portfolio and clear priorities. One of the immediate priorities is to act on the growing evidence that by preventing stroke we can also prevent some dementias, since stroke doubles the chances of developing dementia. All the major organizations dealing with stroke and dementia have endorsed the joint prevention and this approach offers a real possibility to do something about it now.

With current knowledge, we are at the cusp of a transformational change of our approach to the two greatest threats to the brain, stroke and dementia.
CHAIRS

Karl Max Einhäupl  
Charité – Universitätsmedizin Berlin |  
CEO | Germany

Vladimir Hachinski  
World Stroke Organization | Chair,  
Joint Prevention of Stroke and Dementia | Canada

SPEAKERS

Suvarna Alladi  
University of Cambridge |  
National Institute of Mental Health and Neuro Sciences (NIMHANS) |  
Professor | India  
Dementia in the Developing World

Karl Max Einhäupl  
Charité – Universitätsmedizin Berlin |  
CEO | Germany  
Next Steps Forward

Vladimir Hachinski  
World Stroke Organization |  
Chair, Joint Prevention of Stroke and Dementia | Canada  
Preventing Stroke and some Dementias now

Yves Joanette  
CIHR Institute of Aging | Scientific Director  
University of Montreal / World Dementia Council | Professeur Titulaire / Chair | Canada  
New Approaches for Dementia: A Global Perspective

Zaven Khachaturian  
Campaign to Prevent Alzheimer’s Disease by 2020 | President | United States of America  
Dementia: The Urgent Need for New Approaches
KEYNOTE

OPENING CEREMONY

HOST

M8 Alliance:
Charité – Universitätsmedizin Berlin
**CHAIRS**

**Hélène Boisjoly**
University of Montreal | Faculty of Medicine | Dean & Acting President of the World Health Summit 2017 | Canada

**Detlev Ganten**
World Health Summit | President | Germany

---

**SPEAKERS**

**Hermann Gröhe**
Bundesministerium für Gesundheit | Federal Ministry of Health (BMG) | Federal Minister | Germany

**Joanne Liu**
Médecins Sans Frontières | International President | Switzerland

**Werner Baumann**
Bayer AG | CEO | Germany

**Roger D. Kornberg**
Stanford University | School of Medicine | Structural Biology | Professor, Nobel Laureate | United States of America

**Christoph Franz**
Roche Holding Ltd | Chairman, Board of Directors | Switzerland
PROGRAM

MONDAY, OCTOBER 16
This session will explore the opportunities for Big Data to assist governments and health care providers in delivering maximum benefit to society. Big Data will drive fact-based decisions by policy makers and shape how health systems address societal and global challenges in both developed and developing economies. The increased scope, detail and availability of patient and population data will also influence the broader debate around data governance and the associated ethical issues. Our panelists will illustrate the discussion with some case studies of health data uses to help clinical practice management, surveillance, health system management, and research and innovation.
CHAIR

Ross Coppel
Monash University | Faculty of Medicine, Nursing and Health Sciences | Deputy Dean and Director of Research

SPEAKERS

Francesca Colombo
Organization for Economic Cooperation and Development (OECD) | Head of Health Division | France
**Embedding Big Data within the Health System - Health Data Governance**

David Delaney, MD
SAP SE | Chief Medical Officer | United States of America
**Big Data in the Developed World Context**

Maxim Fedorov
Skolkovo Institute of Science and Technology (Skoltech) | Center for Computational and Data-Intensive Science and Engineering | Director | Russia
**How can Big Data help to Answer the Big Health Questions?**

Albena Kuyumdzhieva
European Commission | DG Research & Innovation | Programme Manager-Research/Ethics Review | Belgium
**Big Data Oversight and Ethics**

Ola Rosling
Gapminder Foundation | President & Co-Founder | Sweden
**Big Data for a Fact-Based Worldview**
Neglected Tropical Diseases (NTDs) are a group of tropical infections that affect the world’s poor and marginalized populations. According to the World Health Organization, more than a billion people or one-seventh of the global population suffer from one or more tropical infectious diseases.

Availabililty of treatment, technology transfer, scientific collaboration and knowledge sharing but also research and development are important to move forward against some of the world’s most debilitating and stigmatizing diseases. Partnerships and collaborations can play a crucial role in solving intractable challenges and tackling neglected diseases. Refined diagnostic tests and techniques allow NTD-programs to achieve success. More sensibility, cost-efficiency and good partnerships among academic, philanthropic, pharmaceutical, governmental, and nongovernmental organizations are a must.

Refined diagnostic tests and techniques allow NTD-programs to achieve success. For example: diagnostic testing for lymphatic filariasis (LF) is now more sensitive and cost-efficient, thanks to a partnership among academic, philanthropic, pharmaceutical, governmental, and nongovernmental organizations. The Liverpool School of Tropical Medicine (LSTM) is working on new macrofilaricides acting through an anti-Wolbachia mechanism. Together with Abbvie DNDi is following up on screening hits for parasites causing visceral leishmaniasis and Chagas’ disease, and nematodes causing river blindness and lymphatic filariasis.
CHAIRS

**Carsten Köhler**
University Hospital Tübingen | Institute of Tropical Medicine | Center of Competence | Director | Germany

**Aluisio Cotrim Segurado**
University of São Paulo | Faculty of Medicine | Department of Infectious Diseases | President | Brazil

SPEAKERS

**Achim Hörauf**
University Hospital Bonn | Institute of Medical Microbiology, Immunology and Parasitology | Director | Germany
What could be Game Changers in Filarial Elimination Programs?

**Humphrey D. Mazigo**
Catholic University of Health and Allied Sciences | Senior Lecturer | Tanzania
How to Build up New Partnerships for Innovation?

**David Molyneux**
Liverpool School of Tropical Medicine (LSTM) | Emeritus Professor and Senior Professional Fellow | United Kingdom
The Changing NTD Paradigm - A Core Cross Cutting Component of the SDGs

**Jutta Reinhard-Rupp**
Merck KGaA, Darmstadt | Global Health Institute | Head | Switzerland
What are the Challenges of the Private Sector to Fight Schistosomiasis?

**Monique Wasunna**
Drugs for Neglected Diseases initiative (DNDi) Africa | Director | Kenya
Strengthening Capacity for Visceral Leishmaniasis Clinical Research in Africa: Challenges and Opportunities
NEW STRUCTURES FOR TRANSLATIONAL RESEARCH

Better Ways to Deliver Precision Medicine

HOSTS

German Centers for Health Research (DZG)

Helmholtz Association of German Research Centers e.V.

Translational research is part of a bidirectional continuum in which research findings are moved from the researcher’s bench to the patient’s bedside, but also backwards from clinical findings into mechanistic research. Development of new diagnostic and informatics methods has seen an increasing trend towards more personalized therapeutic approaches. Information on the individual’s genomic/transcriptomic profiles, in combination with lifestyle and environmental factors are integrated to guide medical decision in terms of prevention, diagnosis and treatment of disease. The advent of big data analysis is also offering a reverse approach to personalized medicine.

Starting from large data sets acquired in the clinics, patterns can be identified that link proteins or gene changes that can form the bases to stratifying disease phenotypes. With the aim of better diagnostics and treatments, new structures in research and health care are being experimented. International experts on neurodegenerative diseases (Prof. Pierluigi Nicotera, Germany), cancer (Prof. Alexander Eggermont, France) diabetes (Prof. Henning Beck-Nielsen, Denmark) and internal medicine (Prof. Wieland Voigt, Germany) were invited to present their view on translational research as well as to highlight new structures designed to deliver better precision medicine.
CHAIR

Michael Baumann
German Cancer Research Center | Chairman & Scientific Member of the Management Board | Germany

Pierlugi Nicotera
German Center for Neurodegenerative Diseases (DZNE) | Director | Germany

SPEAKERS

Henning Beck-Nielsen
Odense University Hospital | Head of the Department of Endocrinology | Denmark
Individualized Treatment of Patients with Type 2 Diabetes Based on Pathophysiology

Alexander Eggermont
Gustave Roussy Comprehensive Cancer Center | Director General | France
Cancer Core Europe: A Structured Sustainable Model for Open Science, Translational Research, and Training

Wieland Voigt
Siemens Healthineers | Chief Medical Officer | Germany
From Basic Research to Clinical Innovation - An Industry Perspective
Despite the launch of innovative treatments and solutions during the last decades people are still suffering. 1 out of 2 is not on target. Human and financial resources are needed to cover the needs for information, support and complications.

To either prevent people to become diabetics or to help people with already established diabetes to live full, healthy lives comprehensive solutions have to be developed which combine devices, software, medicine, and professional care. A multi-stakeholder approach is needed.

The workshop discusses the outlook into the future, opportunities we see, best practices we know, and actions we need to take to make it happen.

Let’s shape the future of healthcare together!
CHAIRS

Ricardo Baptista Leite
Portuguese Republic | Member of the Parliament | Portugal

Gilles Litman
Sanofi SA | Global Integrated Care, Diabetes Cardio-Vascular | Chairman | France

SPEAKERS

Ricardo Baptista Leite
Portuguese Republic | Member of the Parliament | Portugal

The Public Health & Political View
Stefanie Gerlach
diabetesDE - German Diabetes Aid | Director of Health Policy | Germany
The Health Policy View

Gilles Litman
Sanofi SA | Global Integrated Care, Diabetes Cardio-Vascular | Chairman | France
The Health & Tech Industry View

Laura Quinn
IDF Europe Young Diabetes Advocate | Final Year Medical Student, University of Birmingham | United Kingdom
The Patients View

Johanna Ralston
World Obesity Federation | CEO | United Kingdom
The Civil Society View

Joachim Spranger
Charité – Universitätsmedizin Berlin | Department of Endocrinology and Metabolic Diseases | Director | Germany
The Scientific View
WORKSHOP

GLOBAL HEALTH SECURITY ENGAGEMENT IN CONFLICT AND CRISIS SITUATIONS

HOSTS

Bundeswehr Command and Staff College
Center for Global Health Engagement (CGHE)
Harvard Medical School
King’s College London

Global Health depends more than ever on the efficiency and outcome of all involved global and regional actors. One of them, the military, with their unique and specific capabilities is assuming more and more tasks in the health sector with the intention support security and stability during or post-conflict situations. Specifically, during crisis and conflict, the health sector is facing all kind of threats to their workforce, financing, infrastructure, and information systems, that require protection and support to prevent a collapse of the health system and with it one of the pillar of human security. Additionally, nations with ineffective health systems can struggle to form effective bilateral or multilateral partnerships to address pandemics, bioterrorism or health-related environmental crises that cross borders.

This workshop highlights critically, the active or passive role of the military in Global Health Security.
CHAIRS

Jillann Farmer  
United Nations  
Director, Medical Services Division  
United States of America

Christian Haggenmiller  
Bundeswehr Command and Staff College  
Lecturer  
Germany

SPEAKERS

Margaret Bourdeaux  
Harvard Medical School  
Instructor in Medicine  
United States of America

Major General Martin Bricknell  
Headquarters Joint Forces Command  
HQ Surgeon General  
Acting Surgeon General  
United Kingdom

Lieutenant General Patrick Godart  
French Ministry of Defence  
Inspector General of the Military Medical Services  
France

Feda Mohammad Paikan  
Ministry of Public Health  
Deputy Minister  
Afghanistan

Richard Sullivan  
Kings College London  
Director, Institute of Cancer Policy and Co-Director of King’s Conflict & Health Research Group  
United Kingdom
Healthcare has developed into a key policy issue that is discussed at both national and international levels. In 2017, the G20 will for the first time include a meeting of national Health Ministers in a forum set to cover topics like health security and antimicrobial resistance.

The health governance issues inherent in the Sustainable Development Goals have underlined how increasing financial and political commitments are central to solving global health challenges which must be dealt with at the highest political level.
CHAIR

Michael J. Klag
Johns Hopkins Bloomberg School of Public Health | Professor & Former Dean | United States of America

SPEAKERS

Dean Jamison
University of California, San Francisco | Professor Emeritus | United States of America
Directions for Development Cooperation in Health: Financing Global Public Goods

Neil Jordan
Microsoft | Health Worldwide | General Manager | United States of America

Georg Schütte
Bundesministerium für Bildung und Forschung / Federal Ministry of Education and Research (BMBF) | State Secretary | Germany
Widening the Scope of Global Health Research – Looking beyond G7 and G20

Anna Babette Stier
Bundesministerium für Gesundheit / Federal Ministry of Health (BMG) | European and International Health Policy | Deputy Director-General | Germany
The New Role of Health in the G20 – Building Resilience, Improving Sustainability, Assuming Responsibility
PANEL DISCUSSION

THE BEAUTY OF IMPACT
Social Tech Pioneers in Public Health

HOST
Bayer Science & Education Foundation

This session showcases impact pioneers from all continents who have developed new solutions for the big challenges in public health and social medicine. It is a tribute to those courageous men and women whose hunger for breakthroughs has enabled them to excel in spheres never imagined. On stage are tech founders and health activists who have dared to brave the unknown for the purpose of shaping the future of humanity. They are icons of progress. Let them inspire you for social innovation and progress in public health.

CHAIR
Thimo V. Schmitt-Lord
Bayer Foundations | CEO | Germany
SPEAKERS

Martin Aufmuth  
One Dollar Glasses Association | Founder & Director | Germany

Marc Buckley  
ANJA | Founder and CEO | Germany

István Deák  
Braille Ring by Tetragon | Co-Inventor and CEO | Austria

Carsten Dierkes  
SANI SOLAR by 3P Tech Filter Systems GmbH | Germany

Brian Gitta  
Matibabu | Inventor & Co-Founder | Uganda

André Habisch  
Catholic University Eichstätt-Ingolstadt | Germany

Frank Hoffmann  
discovering hands | Founder & CEO | Germany – India – Austria – Colombia – Mexico

Christian Keller  
DOCTOR DIAL by African Founders | Co-Founder | Nigeria – Ghana – Kenya

Kalana Prasad Maduwage  
Snake Rapid | Inventor | Sri Lanka

Mary Matthews  
Prompt by Memrica | Founder | United Kingdom

Margaret Nanyombi  
BVKit by HerHealth | Inventor, Founder & CEO | Uganda

Harald Neidhardt  
RFRC by MLove & Cisco | Co-Founder | Germany – Greece – Syria

Bhaumik Sanghvi  
iBreastExam by UE LifeSciences | Founder & CEO | USA – India

Raphael Schönweitz  
RSO Shift GmbH | Co-Founder | Germany – Uganda – Tanzania – India

Akanksha Vyas  
FITED by FITED Inc. | Co-Founder | USA – India – Turkey – Poland
THE SUSTAINABLE DEVELOPMENT GOALS

An Opportunity to Accelerate Political Will and Policy Coherence for Global Health World-Wide?

The SDGs do a remarkable job of illustrating, for a global lay audience, how health is both a product and a determinant of all other global public goods. As the defining development compact of the next 13 years, the SDGs thus provide a timely and powerful window-of-opportunity for health. Ideally, health stakeholders around the world should be empowered by the SDGs, to successfully demand greater political commitment and cross-sectoral policy coherence for health.

This makes sense in theory, but what is the reality? What impact are the SDGs actually having on health on the ground? Representatives of policy research institutions in Africa, Asia, South America, and the South Pacific will describe the political and governance dimensions of SDG roll-out in their countries, with an analysis of what this means for health. This lunchtime panel gives a taste of the contents of a “Global Health Governance” journal special issue on these topics, which will be officially launched at the World Health Summit 2017 in Berlin.
**CHAIRS**

Zoe Boutilier  
International Development Research Centre (IDRC) | Program Officer, Global Health | Canada

Michaela Told  
The Graduate Institute of International and Development Studies | Executive Director, Global Health Centre | Switzerland

**SPEAKERS**

Gonzalo Fanjul  
IS Global Barcelona | Policy Director | Spain  
**Health SDGs and Europe:** The role of Regional Think Tanks

Luiz Augusto Galvão  
Center for International Relations in Health | Senior Researcher | Brazil  
**The 2030 Agenda and Think Tanks in Latin America**

Masuma Mamdani  
Ifakara Health Institute | Research Scientist | Tanzania  
**Health-related SDGs in Africa:** the Case of Tanzania

Saadiya Razzaq  
Sustainable Development Policy Institute (SDPI) | Team Leader / Senior Research Associate | Pakistan  
**Accelerating SDG Implementation in the South Asian Region**

Pablo Vega  
National Health Fund (FONASA) | Chief of Cabinet | Chile  
**Political Engagement and Policy Coherence for Health-related SDGs in Chile**
As the digital and genetics revolutions converge with healthcare into the exciting new field of Digital Health, we are increasingly able to track, manage, and improve both our own health and that of our loved ones. Digital Health is also helping to reduce inefficiencies in healthcare delivery, while at the same time streamlining access, improving quality and making medicine more personalized and precise.

The essential elements that are making the digital health revolution a reality include wireless devices, hardware and software sensing technologies, the Internet, social networking, mobile and body area networks, health information systems, and genomic medicine.

Like any tool, Digital Health is by itself neutral. It can either bring us closer to universal health care, or deepen the divide between the rich and the destitute, the developed and the under-developed. We need to understand how to steer Digital Health to ensure healthy lives and promote well-being at all ages and in all regions of the world. Advances are needed in issues like choosing which technologies should (and should not) be used by national health care systems in regions at different levels of development, on how to control complexity, and keep costs under control.

Digital Health is probably the most important factor that will shape healthcare delivery in the years to come.
**CHAIR**

João Gabriel Silva  
Coimbra Hospital and University Centre (CHUC) | Dean & Acting President of the World Health Summit 2018 | Portugal

---

**SPEAKERS**

**Adalberto Campos Fernandes**  
Ministry of Health | Minister | Portugal  
**Health Care Systems in Transition and Digital Health**

**Arnaud Bernaert**  
World Economic Forum | Global Health and Healthcare Industries | Head | Switzerland  
**Why Would the Doctor Want to See You Now?**

**Steven Hildemann**  
Merck | Global Chief Medical Officer, Head of Global Medical Affairs and Patient Safety | Germany  
**Unlocking Tomorrow’s Cures – Digitalization in the Pharmaceutical Industry**

**Carla Kriwet**  
Royal Philips | Connected Care & Health Informatics | CEO | United States of America  
**From Illegible to Immeasurable – The Digitization of Healthcare**

**Thomas P. Laur**  
SAP SE | President of SAP Health | United States of America  
**Unleashing the Power of Digital: A Technologist’s View of Data-Driven Innovation in Healthcare**

**Elmar Nimmesgern**  
European Commission | Deputy Head of Unit Innovative and Personalised Medicine | Belgium  
**EU Action on Digital Transformation of Health and Care**
VACCINATION APATHY

Vaccination is an effective preventative healthcare measure to help protect against infectious disease, and yet for many diseases and geographical areas, vaccination coverage rates are low. Despite the historic success of immunization in reducing the burden of illness and death, episodes of public concerns and rumours around vaccines have occurred around the world, spreading quickly and sometimes seriously eroding public confidence in immunization – ultimately leading to vaccine refusals and disease outbreaks.

This panel discussion explores the state of vaccine confidence and adult vaccination apathy, and its causes and influences. The impact of vaccination apathy is considered within the context of the globally ageing population, in light of the opportunity vaccination presents for healthy ageing.

Vaccine confidence does not solely apply to those for whom vaccination is appropriate – research has shown that healthcare professionals too are affected by negative publicity around vaccination.

With this in mind, the psychological drivers for, and barriers to adult vaccination for both healthcare professionals and the general public are assessed through the discipline of behavioural economics.

Consideration is given to how a range of stakeholders, including policy makers and the healthcare community, can take learnings from behavioural science to understand and address the emotional barriers to adult vaccination, to help address the challenge of keeping our ageing population well in later life.
CHAIR

Heidi J. Larson
The Vaccine Confidence Project | Director | United Kingdom

SPEAKERS

Jane Barratt
International Federation on Ageing | Secretary General | Canada
Preventative Health: Vaccination as a Tool for Healthy Ageing

Douglas E. Hough
Johns Hopkins Bloomberg School of Public Health | Associate Scientist & Associate Director, Master of Health Administration Program, Health Policy and Management | United States of America
Why do People Avoid Vaccines? A Perspective from Behavioural Economics

Pauline Paterson
London School of Hygiene & Tropical Medicine (LSHTM) | Co-Director, The Vaccine Confidence Project | Co-Director | United Kingdom
Vaccination Apathy: The Role of the Healthcare Provider

Horst von Bernuth
Charité – Universitätsmedizin Berlin | Head of Pediatric Immunology and Infectious Diseases | Germany
The Impact of Infectious Disease in Later Life – The Need for a Lifelong Approach to Vaccination
In recent years, global health security has received increased attention. The Ebola outbreak brought attention to the weaknesses in the systems of preparedness and response. In order to deal with these gaps a number of steps were taken. WHO has committed to improve its emergencies program, while private initiatives have also been developed. Regional organizations such as the EU and the African Union have increased their resolve to address global health security challenges.

Yet despite these initiatives, the world is not ready for the next pandemic. Furthermore, some low-income countries perceive the health security agenda as a device for protecting the developed world from health threats arising from the under-developed world, thereby only advancing the interests of the West.

There is much work to be done in gaining universal acceptance of the global health security agenda and improving collaboration between international, regional and national actors.

However, health security involves more than just infectious disease outbreaks. Health security is also part of wider health systems strengthening and Universal Health Coverage activities, but it is not yet clear how to best synergise these overlapping areas.

Improving global health security is first and foremost a political endeavour. More commitment is required from beyond ministries of health; heads of state across the globe must prioritise health as a political and security issue as well as a medical one.
CHAIR

Wolfgang Ischinger
Munich Security Conference (MSC) | Chairman | Germany

SPEAKERS

Peter Albiez
Pfizer Germany | CEO | Germany

Lord Paul Boateng
Parliament of the United Kingdom | Member of the House of Lords | United Kingdom

Laurie Garrett
Council on Foreign Relations | Senior Fellow for Global Health | United States of America

Richard Hatchett
Coalition for Epidemic Preparedness Innovations (CEPI) | CEO | United Kingdom

Peter Salama
World Health Organization (WHO) | Executive Director, Health Emergencies Programme | Switzerland
The objective of this session is to build an understanding about the critical importance of data transparency and accountability for global health, in particular tools for tracking global health financing, policies and strategies. The speakers come from an academic, foundation, multilateral and NGO background. They will reflect on major topics that are critical for improving global health and reaching SDG 3 (“Ensure healthy lives and promote wellbeing for all at all ages”), including global health R&D, health security, and financing for infectious diseases and reproductive, maternal, newborn, child and adolescent health.

In their contributions, they will highlight the role of new and emerging tools to increase accountability and transparency in global health. The panel will also introduce participants to the Donor Tracker, a free online resource which provides quantitative and qualitative strategic information on 14 major ODA donors. For each donor, the Donor Tracker provides data-driven insights on development funding trends, strategic priorities, and decision-making processes. It also includes ‘Deep Dives’ on global health, health R&D, agriculture and nutrition.

As such, the Donor Tracker is a highly relevant resource for advocates, researchers, think tanks, policy-makers, journalists and academics working in the field of global health and development. The speakers will present examples of how they have used the Donor Tracker to support their work and research.
CHAIR

Christina Schrade
SEEK Development | Managing Director | Germany

SPEAKERS

Christoph Benn
The Global Fund to Fight AIDS, Tuberculosis and Malaria | Director of External Relations | Switzerland
Mobilizing Resources to Finance Global Health

Emanuele Capobianco
The Partnership for Maternal, Newborn and Child Health | Deputy Executive Director | Switzerland
Promoting Accountability for RMNCAH

Dean Jamison
University of California, San Francisco | Professor Emeritus | United States of America
Financing International Collective Action for Health

Kei Katsuno
Global Health Innovative Technology Fund (GHIT) | Investment Strategy & Development | Director | Japan
Advancing the Global Health R&D Pipeline

Anja Langenbacher
Bill & Melinda Gates Foundation | Europe Office | Director | United Kingdom
Investing in Global Health R&D

Maike Röttger
Plan International Germany | CEO | Germany
Evidence-based and Data-driven Advocacy
Despite many efforts to improve patient safety during the past years, morbidity and mortality rates are still alarmingly high. Maternal and children mortality are major health issues in the third world, while sudden cardiac death is the third leading cause of death in industrialised nations – and higher rates of bystander cardiopulmonary resuscitation increase survival by factor 2–4.

This is why joint efforts gained increasing importance for the improvement of health in all humans – irrespective of their origin and age. Present low-threshold and low-cost concepts such as school children education in cardiopulmonary resuscitation found in the “Kids Save Lives” initiative should be implemented in developing and developed countries, and safety for mothers and children need further support by politics, societies, and industry.
CHAIR

Bernd Walter Böttiger
University of Cologne | Department of Anaesthesiology and Intensive Care | Director | Germany

SPEAKERS

Lance B. Becker
Northwell Health | Department of Emergency Medicine | Chair | United States of America
Cardiac Arrest and Resuscitation – A Time to Act / IOM Statement

Bernd Walter Böttiger
University of Cologne | Department of Anaesthesiology and Intensive Care | Director | Germany
Kids Save Lives – School Children Education in CPR / Health and Social Skills

Götz Bosse
Charité Universitätsmedizin Berlin | Department of Anesthesiology and Operative Intensive Care Medicine | Senior Physician | Germany
Quality Management Programs to Reduce Maternal Mortality in the Third World

Anita Kale
National University Hospital | Women’s Centre | Division of Maternal Fetal Medicine | Consultant | Singapore
Maternal Mortality in the World

Tore Lærdal
Laerdal Medical Corporation | CEO | Norway
Global Resuscitation Alliance, and its Relevance also to Low Medium Income Countries – including for Maternal / Newborn / Child Health

Hian Tat Ong
National University Hospital | Division of Paediatric Neurology | Head & Senior Consultant | Singapore
Do’s and Don’t’s for the Under Five
At the beginning of the 21st century, the book on infectious diseases is far from being closed. Increasing antibiotic resistance, emergence of new pathogens, together with changes in pathogen distribution due to altered climate and mobility and the rise in the undertaking of invasive medical procedures present global challenges. This threat is further enhanced by a drastic lack of (new) effective drugs as well as by insufficient preventive and diagnostic possibilities.

In particular, vulnerability to sepsis is increasing on a global scale and is now the third leading cause of death in the world. Sepsis refers to the life-threatening condition in which the body fights a severe infection that has spread into the bloodstream, often resulting in organ failure. As well as constituting a life threatening condition, sepsis is one of the most costly conditions regarding treatment, in 2011 more than 20 billion dollars spent on fighting the disease in the US alone. Inconsistency in terms of recognition and assessment of symptoms continues to constitute a serious barrier to addressing the disease.

This session focuses on the threats posed by underestimated pathogens such as human pathogenic fungi and multidrug-resistant bacteria as well as on strategies to effectively diagnose and efficiently treat sepsis in its early stages.
CHAIR

Bernhard Hube
Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (HKI) | Department of Microbial Pathogenicity Mechanisms | Head | Germany

SPEAKERS

Vida Hamilton
Health Services Executive | National Clinical Lead Sepsis | Ireland
The National Sepsis QI Programme of Ireland

Oliver Kurzai
Julius Maximilians University of Wuerzburg | Medical Microbiology and Mycology | Professor and Chair | Germany
Challenges in Infection Control – Invasive Mycoses as a Case Study

Ulrich Schaible
Research Center Borstel - Leibniz-Center for Medicine and Biosciences | Head of Cellular Microbiology | Germany
The Global Challenge of Infections with Antibiotic Resistant Bacteria such as Tuberculosis

Markus Weigand
German Sepsis Society | President | Germany
Fulfilling the Goals of the Resolution of the World Health Assembly
WORKSHOP

PROMOTING R&D CAPACITY AND MANUFACTURING

HOSTS

European and Developing Countries Clinical Trials Partnership (EDCTP)
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ)
World Health Organization (WHO)

Organized by WHO/TDR and EDCTP, the panel will critically reflect on current needs and gaps to enhance R&D capacity and manufacturing in low and middle income countries (LMIC). The panelists will explore several themes, including (1) various capacity support mechanisms; (2) harmonization through working with all partners and contribution of these efforts to SDGs 7, 9 and 17; (3) new public-private partnerships models; (4) need to assess and demonstrate impact of the efforts; and (5) co-funding and joint priority setting with LMIC.

The panel session will start with an introduction of the current state of capacity support for health research, followed by a debate of panelists representing various stakeholders and will conclude with an interaction with the audience. This session will generate interest from a diverse audiences attending the Summit, such as funders and funding initiatives, health research leaders, private sector, individual researchers and policy makers at different levels.

It is anticipated that the audience will equally contribute to the discussion and their input is expected to contribute to the summary recommendations that will guide all stakeholders for further action.
CHAIRS

Garry Aslanyan  
World Health Organization (WHO) | Special Programme for Research and Training in Tropical Diseases (TDR) | Manager of Partnerships and Governance | Switzerland

Ole F. Olesen  
The European & Developing Countries Clinical Trials Partnership (EDCTP) | Director | The Netherlands

SPEAKERS

Geoffrey Banda  
Innogen – Health and Innovation | Co-Director | United Kingdom
The Link between Local Pharmaceutical Manufacturing and Local Health Systems Strengthening

Siaka Debe  
National Center for Research and Training on Malaria (CNRFP) | Clinical Researcher | Burkina Faso
Capacity Building in LMICs through Innovative Fellowships

Detlef Böcking  
DLR Project Management Agency on behalf of the Federal Ministry of Education and Research (BMBF) | Global Health Research | Head | Germany
Capacity Building in Sub-Saharan Africa by Means of Networking, Mentorship and Research Excellence

Jutta Reinhard-Rupp  
Merck KGaA, Darmstadt | Global Health Institute | Head | Switzerland
The Pediatric Praziquantel Consortium: A New Public-Private Partnership to Fill the Gap of an High Unmet Medical Need in Young Children
SOCIAL EVENT

WORLD HEALTH SUMMIT NIGHT

18:30 – 23:00

HOST

M8 Alliance

The World Health Summit Night is the central social event with food, drinks and entertainment.

It hosts the award ceremony of the Startup Track, presented to the winner by German Minister of Health Hermann Gröhe.

Every participant of the World Health Summit is invited, external guests can buy tickets on-site (€40).
SPEAKERS

Hermann Gröhe
Bundesministerium für Gesundheit / Federal Ministry of Health |
Federal Minister |
Germany

Hélène Boisjoly
University of Montreal |
Faculty of Medicine |
Dean & Acting President of the World Health Summit 2017 |
Canada

Detlev Ganten
World Health Summit |
President |
Germany

João Gabriel Silva
Coimbra Hospital and University Centre (CHUC) |
Dean & Acting President of the World Health Summit 2018 |
Portugal
The role of the public health community in responding to the health impacts of war and conflict has become increasingly important in the context of the changing nature of war and conflict. While the global health community may have limited power to curb the aggression and belligerence of political and military leaders seeking out war and conflict, it can promote informed and open public debate about the causes of war and conflict by providing timely and credible information on the expected and actual health consequences of conflict. The health community also has an important role in preventing and treating injury and disease, as well as monitoring the impact and the conduct of war within the legal framework set out by the Geneva Conventions and other instruments of international law.
**CHAIR**

**Hélène Boisjoly**  
University of Montreal | Faculty of Medicine | Dean & Acting President of the World Health Summit 2017 | Canada

---

**SPEAKERS**

**Christine Beerli**  
International Committee of the Red Cross (ICRC) | Vice-President | Switzerland

**Susanna Krüger**  
Save the Children Germany | CEO | Germany

**Tewodros Melesse**  
International Planned Parenthood Federation (IPPF) | Director General | United Kingdom

**Axel Radlach Pries**  
Charité – Universitätsmedizin Berlin | Dean | Germany

**Ahmad Tarakji**  
Syrian American Medical Society | President | United States of America
The concept of One Health can be defined as the collaborative effort of multiple disciplines – working together locally, nationally and globally – to attain optimal health for people, animals and the environment.

The session will focus on key challenges for science, health policy and society deriving from the understanding that individual and population health can only be maintained within healthy ecosystems. The UN Sustainable Development Goals acknowledge the relevance of the dynamic interaction between humans, animals and the environment which has major public health implications.

Humans and human health continue to change in future. To promote e.g. precision medicine, one has to be aware of ongoing human evolution, global variation and the impact of the environment. Evolutionary Medicine provides such a framework by combining perspectives from evolutionary biology, clinical medicine and connected fields such as history. A comprehensive understanding of critical future challenges of human health on all levels needs such a holistic approach.

The elements – humans, animals, pathogens, nature in general and even technology and social aspects such as culture – are interrelated. Biomedical technology such as reproductive medicine, regenerative medicine and GWAS-based therapies will heavily have a major impact on human health in future. Understanding of both, natural and men-made evolution of resistance genes and general pathogen adaptations provide critical knowledge for future evidence-based medical interventions.
CHAIR

Bill S. Hansson  
Max Planck Society | Max Planck Institute for Chemical Ecology | Director | Germany

SPEAKERS

Iain D. Couzin  
Max Planck Society | Max Planck Institute for Ornithology | Director | Germany  
Social Contagion and Collective Decision Making in Animal Groups

Frank Rühli  
University of Zurich | Institute of Evolutionary Medicine, Faculty of Medicine | Director | Switzerland  
Evolutionary Medicine: Ongoing Evolution and Global Perspectives on Human Health

Paul Verschure  
N-RAS Center for Autonomous System and Neuro-Robotics | Director | Spain  
The Network Medicine of Brain Health: Linking Genotype, Phenotype and Environment in the Service of Wellbeing

Lothar H. Wieler  
Robert Koch Institute | President | Germany  
One Health at the Human-Wildlife Interface in Sub-Saharan Africa
Ensuring equitable access to universal health coverage has many dimensions. New models are emerging around the world which ensure inclusiveness by strengthening social participation. These include new mechanisms like people’s health assemblies and other forms of participation that ensure citizens and patients voices in the setting of priorities. The recognition of social participation is also reflected in the strong engagement of civil society in the new global Alliance for UHC 2030. Strengthening accountability and advocacy are central to accelerate progress towards universal health coverage.
SPEAKERS

Danny Edwards
Access to Medicine Foundation | Research Programme Manager | The Netherlands
Access to Medicines Index: What Could the Private Sector do More

Iraj Harirchi
Ministry of Health and Medical Education | Undersecretary | Iran
Expanding Access to Universal Health Coverage in Iran

Dagnan N’Cho
Ministry of Health and the Fight against AIDS | Director General of Health | Ivory Coast
UHC – The Critical Role of Communities and Community Health Workers

Ophra Rebiere
Sanofi | Vice President, Head of Corporate Social Responsibility | France
The Private Sector Contribution in Ensuring Social Participation

Kevin Watkins
Save the Children UK | CEO | United Kingdom
UHC – How Does Civil Society Make the Difference in Achieving Equitable Progress

CHAIRS

Ilona Kickbusch
The Graduate Institute of International and Development Studies | Global Health Center | Director | Switzerland

Amirhossein Takian
Tehran University of Medical Sciences | Department of Global Health and Policy | Chair | Iran
Since the beginning of evolution, humans and pathogens have been locked in a continuous arms race; health and disease were and continue to be directly linked with cultural and population changes, providing important possible lessons for dealing with today’s health challenges.

Ten thousand years ago in the Early Neolithic period, the shift to a sedentary lifestyle, larger populations and domesticated animals resulted in an increase of infectious diseases. Epidemics have since then shaped human history, including the colonization of the New World as well as the Black Death.

The link between cultural and economic changes and the spread of pandemics has been a continuous source of debate. Recent genomic analyses support the notion that the Y Pestis was the cause of the Black Death pandemic and the Justinian Plague (Wagner et al. 2014, Bos et al 2011). These findings enabled historians to uncover the significance of Mediterranean, African and Asian communications systems in explaining the spread of diseases. The spread of pathogens has also been linked to intensified trade and human mobility. The Roman communication system and the Chinese Silk Road boosted world economic activity yet also facilitated the transmission of diseases. These findings shed new light on the possible impact and consequences of modern migration in relation to understanding and responding to new health threats.
CHAIR

Johannes Krause
Max Planck Institute for the Science of Human History | Director | Germany

SPEAKERS

Mark Achtman
University of Warwick | Warwick Medical School | Professor of Bacterial Population Genetics | United Kingdom
Typhoid Fever in 13th Century Norway

Sebastien Calvignac-Spencer
Robert Koch Institute | Senior Researcher | Germany
Emerging Infectious Diseases from non-Human Primates in Africa – One Past Health Approach (OPAH)

Angelika Messner
Kiel University | Head of China Centre | Germany
The Evolution of the Idea of Chuanran 傳染 in China

David Napier
University College London | Professor of Medical Anthropology | United Kingdom
The Effects of Migration on Immunity

Anne C. Stone
Arizona State University | School of Human Evolution & Social Change | Regents’ Professor | United States of America
Tuberculosis Epidemics in the pre-Columbian New World
The recent back-to-back occurrence of two viral epidemics (Ebola and Zika) that blossomed into public health emergencies of international concern has highlighted the shortfalls of the global and local diagnostic response. Diagnostics are crucial in mitigating the effect of disease outbreaks. As we come together to develop the global health infrastructure necessary to better face future infectious disease threats, the role of diagnostics must be considered foremost, and mechanisms established to carry out the logistical, financial, political, and technical work required to ensure diagnostic preparedness for the inevitable next epidemic. CEPI·dx is a new global partnership focused on diagnostics for health threats prioritized by WHO. CEPI·dx has been initiated by CEPI and FIND to drive the development and delivery of appropriate diagnostics and allow the rapid response to future epidemics by strengthening diagnostic preparedness for a safer world.

This panel will allow participants to share their experience and their points of view on how the world can prepare to allow rapid response to future epidemics.
CHAIR

**Catharina Boehme**
Foundation for Innovative New Diagnostics (FIND) | CEO | Switzerland

SPEAKERS

**Arlene Chua**
Médecins Sans Frontières | MSF Diagnostic Working Group | Leader | Switzerland

**Richard Hatchett**
Coalition for Epidemic Preparedness Innovations (CEPI) | CEO | United Kingdom

**Hans-Jochen Heinze**
University of Magdeburg | Clinic of Neurology | Director | Germany

**Nadia Khelef**
Institut Pasteur | Senior Advisor for Global Affairs | France

**Lars Schaade**
Robert Koch Institute | Vice President | Germany

**Robert J. Stokes**
Nielsen Tele Medical GmbH | CEO | Germany
When it comes to fighting infectious diseases, vaccines offer top economic and social value, and they also represent the best means for controlling and eliminating dangerous communicable pathogens. Intensified global efforts to step up vaccine research and development are therefore a must, especially for neglected tropical diseases. A central challenge is that in some developed countries, where popular perceptions no longer view infection or epidemics as a serious risk, mindsets will need to change.
CHAIR

Peter Piot
London School of Hygiene & Tropical Medicine (LSHTM) | Director & Professor of Global Health | United Kingdom

SPEAKERS

Richard Hatchett
Coalition for Epidemic Preparedness Innovations (CEPI) | CEO | United Kingdom
Preventing Future Epidemics

Heidi J. Larson
The Vaccine Confidence Project | Director | United Kingdom
The Vaccine Confidence Project: The Importance of Building Public Trust in Vaccines

Stefan Kaufmann
Max Planck Institute for Infection Biology | Director | Germany
TB Vaccine Candidate from the Drawing Board to Clinical Efficacy Trial: An Example for a PPP between Germany and India
Digital technologies are on the way to transform access to health care tremendously. Electronic patient records, new medical data infrastructures to close current data gaps, mobile applications that support diagnostic and therapeutic practices, telemedicine that allows health care over distances, or innovative logistics infrastructures like the use of drones for the delivery of drugs to remote areas are just a few examples of how digital tools can be used for providing better health care. Without any doubt, the future of health is digital. The applications seem to be infinite and they promise to be cost-effective, fast and easy to implement while assuring high quality standards. However, the effective implementation of scalable digital health solutions face numerous challenges and lessons from practice show that currently not all promises can be met. There is an increasing need to harmonize technologies, allow interoperability between different applications, or design public health systems that can handle innovation. Yet, the pressure to find funds for new projects makes it difficult to openly debate failure and challenges. Leading international experts will discuss the effects of the global digital transformation for health systems in the developing world. The aim of this session is to identify the major chances and challenges in digital health and to formulate recommendations on how to design the future of digital global health.
**CHAIRS**

**Norman Schräpel**  
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) | Policy Advisor | Germany

**Juliane Zielonka**  
Health 2.0 Berlin | Co-Organizer | Germany

---

**SPEAKERS**

**Salif Samake**  
Ministry of Health and Public Hygiene | General Secretary | Mali

**Michael Adelhardt**  
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) | Head of Section Health, Social Protection and Inclusion | Germany

**Heidi Good Boncana**  
Global Digital Health Network | Co-Chair | United States of America

**Nadi Kaonga**  
citiesRISE | Technology Advisor | United States of America

**Titus Kühne**  
Charité - Universitätsmedizin Berlin | Institute of Computer-Assisted Medicine | Director | Germany

**Natalia Pshenichnaya**  
GSMA | Head of mNutrition | United Kingdom

**Norman Schräpel**  
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) | Policy Advisor | Germany

**Heidi Good Boncana**  
Global Digital Health Network | Co-Chair | United States of America

---

**Juliane Zielonka**  
Health 2.0 Berlin | Co-Organizer | Germany

**Nadi Kaonga**  
citiesRISE | Technology Advisor | United States of America

**Titus Kühne**  
Charité - Universitätsmedizin Berlin | Institute of Computer-Assisted Medicine | Director | Germany

**Natalia Pshenichnaya**  
GSMA | Head of mNutrition | United Kingdom

**Norman Schräpel**  
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) | Policy Advisor | Germany

**Heidi Good Boncana**  
Global Digital Health Network | Co-Chair | United States of America

---

**Juliane Zielonka**  
Health 2.0 Berlin | Co-Organizer | Germany

**Nadi Kaonga**  
citiesRISE | Technology Advisor | United States of America

**Titus Kühne**  
Charité - Universitätsmedizin Berlin | Institute of Computer-Assisted Medicine | Director | Germany

**Natalia Pshenichnaya**  
GSMA | Head of mNutrition | United Kingdom

**Norman Schräpel**  
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) | Policy Advisor | Germany

**Heidi Good Boncana**  
Global Digital Health Network | Co-Chair | United States of America
Successful institutions need good leaders. And whether they are in high income countries or poorer countries, institutions providing healthcare, educating future physicians or promoting the public’s health are no different. Yet decision-makers in such institutions are often appointed from among people trained in medicine, with little formal training in leadership to prepare them for these roles. The InterAcademy Partnership (IAP) for Health Young Physician Leaders (YPL) program aims to bridge this gap. Launched in 2011, to date some 155 young physicians from some 45 countries have participated in six international and one regional editions of this personalized leadership training program (a dedicated IAP for Health YPL Directory is available here: www.iamp-online.org/iamp-young-physician-leaders-directory). In addition, a group of alumni were introduced to the 2016 World Health Assembly in Geneva. IAP for Health YPL training events take place immediately prior to the World Health Summit. This session will be designed by the 23 participants of the 2017 event taking place on 12–14 October and will address challenges shared by young physicians across low, middle and high income countries and solutions that they see for making the changes needed to improve health.

The session is open to everyone – students, young medical personnel at the start of their careers, as well as delegates holding more senior positions.
**CHAIRS**

**Jo Ivey Boufford**  
InterAcademy Partnership (IAP) for Health | YPL Program Leader | United States of America

**Nora Ilona Grasseli**  
ESMT European School of Management and Technology | Program Director | Germany

**SPEAKERS**

Selected from among the 2017 Cohort of Young Physician Leaders
The 2030 Agenda for Sustainable Development aims to shape a very different world. The factors that now govern the well-being of the human condition, and the planet that sustains it, are no longer so discrete. Health plays a central role in this challenging agenda as a precondition, outcome, and indicator of a sustainable society. The SDGs recognize that health challenges can no longer be addressed by the health sector acting alone – nearly everyone of the SDGs can contribute to improving health and wellbeing. The SDGs also underline that governments will need the support of many other stakeholders to address the determinants of health and priority health issues such as NCDs, UHC and poverty related diseases.
CHAIR

Ilona Kickbusch
The Graduate Institute of International and Development Studies | Global Health Center | Director | Switzerland

SPEAKERS

Justin McCarthy
Pfizer Inc. | Global Policy and International Public Affairs | Senior Vice President | United States of America
What Changes for the Private Sector? Does it live up to its Global Responsibilities in the SDG Context? Especially in Health?

Matshidiso Rebecca Moeti
World Health Organization (WHO) | WHO Regional Office for Africa | Regional Director for Africa | Congo
How is WHO and WHO/Africa in Particular Approaching the Intersectoral Approach to the SDGs? Will the WHO Work Differently?

Gerd Müller
Federal Ministry for Economic Cooperation and Development (BMZ) | Federal Minister | Germany
How is Germany Contributing to the Implementation of the SDGs – At Home and Abroad?

Elhadj As Sy
International Federation of the Red Cross (IFRC) | Secretary General | Switzerland
Can the SDGs Really Help Address the Many Disasters and Emergencies we are Facing?
The global health community is increasingly focused on supply chain challenges as multi-lateral donors disburse grant funding for commodity procurement, countries need to be prepared to efficiently absorb and utilize these funds for maximum impact. Even when procurement capacity is strong, last mile delivery challenges persist. The supply and delivery of health products and solutions are among the key challenges to access that are often overlooked. Even the most innovative and effective medicines can be rendered useless if they are not safely and effectively delivered to the patients in need.

Effectively addressing supply chain and delivery challenges requires an inclusive approach that leverages the collective expertise and experiences of diverse stakeholders. Multi-stakeholder collaborations and public-private partnerships are becoming more and more instrumental in addressing these key challenges and accelerating access to more affordable, safe and quality medicines. Equally important and often overlooked are the upstream supply chain challenges where limited collaboration among private sector companies can lead to inefficient and more expensive delivery systems.

Recognizing these bottlenecks to effective supply chain and delivery systems, 13 private sector partners came together in May 2014 to launch The Accessibility Platform. A global health initiative, spear-
headed by the private sector, which aims at promoting information exchange, best practice sharing and fostering multi-stakeholder dialogue and collective actions at the global, regional, and country levels.

This multi-stakeholder panel will provide an overview of key challenges, identify potential areas for collective action and highlight best practices to jointly address supply chain and delivery issues in a holistic manner to strengthen health systems.

**SPEAKERS**

**H.E. Kwaku Agyeman-Manu**  
Ministry of Health | Minister | Ghana

**Manfred Bruch**  
F. Hoffmann-La Roche Ltd. | Head of Partner Collaborations | Switzerland  
**Last Mile / Capacity Building (Emerging Markets in General)**

**Cristina Castro González de Vega**  
F. Hoffmann-La Roche Ltd. | Africa Strategy PT Program Lead | Switzerland  
**Last Mile / Capacity Building (Africa SSA)**

**Martin Ellis**  
The Global Fund to Fight AIDS, Tuberculosis and Malaria | Head of Supply Chain | Switzerland  
**Sharing Supply Chain Best Practices and Partnership Collaboration Experiences**

**Philippe Francois**  
Novartis AG | Vice President, Global Head of Supply Chain | Switzerland  
**First Mile Delivery (Emerging Markets or Africa?)**

**Rüdiger Krech**  
World Health Organization (WHO) | Office of the Assistant Director-General | Health Systems and Innovation | Director | Switzerland

**Frédérique Santerre**  
Merck | Global Head, Access to Health, Group Communications | Switzerland  
**Awareness and Advocacy**
United Nations Member States have a shared commitment and a common interest in achieving the Sustainable Development Goals by 2030. Achieving this will require significant investment, innovation and partnerships in Africa. It will benefit from integrated approaches to health, development and security, as well as consensus-building, information sharing and knowledge exchange.

The Panel Discussion will explore lessons learned and opportunities arising from the aspirations of African Union’s Agenda 2063, the Third Industrial Development Decade for Africa, 2016–2025, and Germany’s experience as President of the G20, and in uniting diverse stakeholders and the work of parliamentarians, civil society, faith-based institutions and private sector bodies in representing stakeholders while also delivering value and creating opportunities.

This session will consider how distinct goals, such as ending the AIDS epidemic in Africa, can not only be achieved through integrated efforts, but also how the tools and approaches can be used for social transformation and development and contribute to achieving other SDGs without leaving anyone behind.

Speakers from communities, the private sector, science and politics will draw on their experiences and strategies to explore opportunities and progress in collaboration and innovation in Africa.
CHAIRS

Roland Göhde  
German Healthcare Partnership (GHP) | Chairman of the Board | Germany

Luiz Loures  
The Joint United Nations Programme on HIV/AIDS (UNAIDS) | Deputy Executive Director | Switzerland

SPEAKERS

H.E. Kwaku Agyeman-Manu  
Ministry of Health | Minister | Ghana

Bernard S. Haufiku  
Ministry of Health and Social Services | Minister | Namibia

Chikwe Ihekweazu  
Nigeria Centre for Disease Control | CEO and National Coordinator | Nigeria

Bakhuti Shengelia  
Novartis Foundation | Head, Global Health Portfolio | Switzerland

Dazhu Yang  
International Atomic Energy Agency | Deputy Director General | Austria
Healthcare and public procurement both suffer from high levels of corruption and the point at which they converge, procurement within healthcare, is an acute vulnerability that is routinely exploited. But governments and civil society organisations are now taking action to protect the lives of citizens by implementing open contracting.

In several countries, corruption has been significantly reduced throughout the procurement process following the implementation of open contracting. This workshop brings together 3 vibrant and powerful case studies from Honduras, Ukraine and Nigeria that make the case for open contracting in the health sector.

Ensuring that funds are correctly invested has the potential to significantly improve service quality and health systems functioning, and can lead to better health outcomes overall. This is particularly important to ensure that national health systems are robust enough to withstand major disease outbreaks. Come to this workshop to learn how open contracting can help save lives.
CHAIR

Peter Eigen
Transparency International | Founder and Chairman of the Advisory Council | Germany

SPEAKERS

Abram Huyser-Honig
Association for a More Just Society | Editor, Revistazo.com | Honduras
Opening Up Medicine Procurement in Honduras

Joseph Kraus
The ONE Campaign | Transparency & Accountability | Director | United States of America
The Value of Open Contracting for Nigeria’s Health Sector

Viktor Nestulia
Transparency International Ukraine | Innovation Projects Programme | Director | Ukraine
Everyone Sees Everything – Improving Healthcare Procurements in Ukraine
Anti-microbial resistance (AMR) renders antibiotics ineffective, via the reaction of micro-organisms when exposed to anti-microbial drugs. Misuse of antibiotics, poor infection control and inadequate sanitary conditions across the globe has encouraged the spread of AMR to the detriment of both the economy as well as mortality rates, costing an annual estimated 1.5 billion Euros to the European Union healthcare system and threatening the achievement of the SDGs.

Without effective antimicrobials, standard medical procedures such as organ transplants, cancer chemotherapy, diabetes management and surgery become high risk procedures. The cost of healthcare rises for those affected by AMR due to longer duration of illnesses, additional tests and more expensive drugs. In 2014 approximately 480,000 people developed drug resistant TB, whilst in some countries treatment medication for E Coli is ineffective in more than half the patients. This session focuses upon strategies to ensure both continued funding for medical research as well as efficient production, availability and dissemination of vaccines and other medicines to those who require them.
MODERATOR

Astrid Frohloff
TV Moderator

SPEAKERS

Thomas B. Cueni
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director General | Switzerland

Karin Knufmann-Happe
Federal Ministry of Health | Director General for Health Protection, Disease Control and Biomedicine | Germany

Jeremy Knox
Wellcome Trust | Drug-Resistant Infections | Policy Lead | United Kingdom

Rüdiger Krech
World Health Organization (WHO) | Office of the Assistant Director-General | Health Systems and Innovation | Director | Switzerland
Partnerships between universities and hospitals of Southern and Northern countries are a perfect example of the new generation of alliances between governments, business and civil society for a joint response to global health challenges including antimicrobial resistance, infectious and noncommunicable diseases.

Institutional health partnerships are collaborative platforms for professional exchanges between peer clinicians and offer a new business model for private companies from the health sector. The benefits of these twinning arrangements are felt all round: institutional North-South and South-South collaboration between healthcare providers strengthen knowledge, access and networks on all sides and improve health systems and services alike.

This session offers the opportunity to members of the public sector both in Northern and Southern countries, to representatives of the private industry and to the civil society to get to know each other, understand diverse motivations and explore how institutional health partnerships may be the tool to make innovation accessible in resource-poor settings and a mean to work jointly for mutual benefit.
CHAIR

Brigitte Jordan-Harder
ESTHER Germany | Senior Consultant and Health Specialist for Health Partnership Programs | Germany

SPEAKERS

Klaus Brill
Bayer AG | Corporate Commercial Relations | Vice President | Germany

Ibrahim Cunaku
VAMED Management und Service GmbH | Deputy Head IT | Austria

Andrew Jones
Tropical Health and Education Trust (THET) | Head of Partnerships and ESTHER Alliance for Global Health Partnerships | United Kingdom

Farid Lamara
European ESTHER Alliance | Secretary General | France

Augustin Sendegeya
University Teaching Hospital of Butare (CHUB) | Director | Rwanda

Heiko Warnken
German Ministry for Economic Cooperation and Development (BMZ) | Head of Division, Health, Population policy and Social Protection | Germany

Brigitte Jordan-Harder
ESTHER Germany | Senior Consultant and Health Specialist for Health Partnership Programs | Germany
Over the past several years, Public Health has been in the ascendancy as we have realised the necessity of multiple approaches to tackle the world’s major health problems and achieve the Sustainable Development Goals. Coincidentally, we have seen a revolution in educational methods and exposure, with the advent of MOOCs, other forms of online learning and innovative approaches to mobilising the future health workforce.

In this session, members of the M8 Alliance will present recent developments in their educational endeavours in Public Health which have been directed towards enhancing engagement and innovation.
CHAIRS

Ben Canny
University of Tasmania | Faculty of Health | Head of Medicine | Australia

Johanna Hanefeld
London School of Hygiene & Tropical Medicine (LSHTM) | Associate Professor Health Policy and Systems | United Kingdom

SPEAKERS

Helen Ackland
Monash University | Department of Epidemiology and Preventive Medicine | Senior Lecturer | Australia

Priorities in Teaching Refugee and Asylum-seeker Health

Dina Balabanova
London School of Hygiene & Tropical Medicine (LSHTM) | Department of Global Health and Development | Associate Professor in Health Systems & Policy | United Kingdom

Strengthening Health Policy and System Research to Promote Global Health

Frédéric Dardel
Paris Descartes University | President | Frankreich

Emerging Trends in Public Health Education

Rébecca Grojsman
University of Geneva & Centre Virchow Villermé for Public Health | Scientific Collaborator | France

Nutrition and Climate Change Education in MPH and Medical Curricula

Tobias Kurth
Charité Universitätsmedizin Berlin | Institute of Public Health | Director | Germany

Innovative Methodology as a Prerequisite for Approaching Emerging Global Health Issue

Amirhossein Takian
Tehran University of Medical Sciences | Department of Global Health and Policy | Chair | Iran

Computer-based Simulation to Integrate SDH in Medical Students’ Curriculum
HOW TO GET TO THE WORLD HEALTH SUMMIT

Kosmos
Karl-Marx-Allee 131a
10243 Berlin
Germany
From Tegel Airport (TXL)
Take the bus line “TXL” to “Alexanderplatz” and change to the underground line “U5” in the direction of “Hönow”. Exit at the third stop at “Weberwiese”. The Kosmos will be 300 meter down the road to the east.

**Duration:** about 60 minutes  
**Ticket:** “Berlin Tarifgebiet A-B” (€2.80)

From Schönefeld Airport (SXF)
Take the train “RE7” in the direction of “Hauptbahnhof”, exit at “Alexanderplatz” and change to the underground line “U5” in the direction of “Hönow”. Exit at the third stop at “Weberwiese”. The Kosmos will be 300 meter down the road to the east.

**Duration:** about 40 minutes  
**Ticket:** “Berlin Tarifgebiet A-B-C” (€3.40)

From Berlin, Hauptbahnhof (Mainstation)
Take the train line “S7” in the direction of “Ahrensfelde”, exit at “Alexanderplatz” and change to the underground line “U5” in the direction of “Hönow”. Exit at the third stop at “Weberwiese”. The Kosmos will be 300 meter down the road to the east.

**Duration:** about 20 minutes  
**Ticket:** “Berlin Tarifgebiet A-B” (€2.80)

From Berlin, Alexanderplatz
Take the underground line “U5” in the direction of “Hönow”. Exit at the third stop at “Weberwiese”. The Kosmos will be 300 meter down the road to the east.

**Duration:** about 10 minutes  
**Ticket:** “Berlin Tarifgebiet A-B” (€2.80)

By car
If you arrive by car you can use the underground parking lot right at the venue.

**Berlin WelcomeCard**
The Berlin WelcomeCard enables free travelling with all public transport services, discounts of at least 25% and up to 50% at around 200 participating partners, and a travel guide with various tour suggestions and insider tips. You can order your ticket at www.berlin-welcomecard.de/en
<table>
<thead>
<tr>
<th>Hotel Name</th>
<th>Address</th>
<th>Distance to venue</th>
<th>Single Room</th>
<th>Double Room</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong> RAMADA Hotel Berlin-Alexanderplatz</td>
<td>Karl-Liebknecht-Str. 32</td>
<td>8 min (car)</td>
<td>€119.00</td>
<td>€129.00</td>
</tr>
<tr>
<td></td>
<td>Phone: +49 (0) 30 2389433</td>
<td>15 min (subway)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2</strong> Park Inn by Radisson Berlin</td>
<td>Alexanderplatz 7</td>
<td>7 min (car)</td>
<td>€109.75</td>
<td>€119.75</td>
</tr>
<tr>
<td></td>
<td>Phone: +49 (0) 30 3010411-0</td>
<td>12 min (subway)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ACCESS TO THE VENUE / SECURITY

To enter the World Health Summit venue participants are required to present a valid identity card / passport or a similar personal identification document (photo included). Please be advised that due to security reasons, all participants will be subject to a security check including a passport identification confirmation. We kindly ask you to refrain from bringing your luggage to the venue, as this will slow down the security check process.

AVAILABILITY

Please note that the capacity of the venue and of single session rooms is limited. If the maximum number of participants is reached, the organizers reserve the right to refuse access.

CLOAKROOM

The cloakroom is located on the left side of the venue and open during the whole event.

COFFEE BREAKS

Refreshments will be served during the coffee breaks.

CURRENCY

The currency used in Berlin is the Euro (€ or EUR). Automated teller machines (ATMs), are located everywhere in Berlin and they accept most main credit cards such as Visa, Mastercard and American Express.

EMERGENCY NUMBERS

Fire: 112
Ambulance: 112
Police: 110

FILMING AND TAKING PICTURES

The organizer will provide a broad spectrum of pictures and other graphical material for the representation of all World Health Summit events. These files will be made available at www.worldhealthsummit.org.

HOMEPAGE

For up-to-date information regarding the World Health Summit, please visit www.worldhealthsummit.org.
INSURANCE AND LIABILITY

The organizers cannot accept liability for personal injury, loss of or damage to belongings of participants, either during or as a result of the World Health Summit. Please check the validity of your own insurance. Attendees are advised to arrange their own adequate travel and medical insurance for medical treatment, accidents, cancellation of bookings etc. No responsibility will be accepted by the World Health Summit organizers.

INTERNET/WIRELESS LAN

Complimentary Wi-Fi will be available within the venue:
Name: WorldHealthSummit
Password: #WHS2017

LANGUAGE

The official World Health Summit language is English. There will be no simultaneous translation.

LUNCHES

Lunches will be available during the lunch breaks.

MEDIA

Media representatives have access to all official sessions of the World Health Summit. Prior accreditation is required via www.worldhealthsummit.org/media/accreditation

MOBILE PHONES

As a courtesy to speakers and other attendees, we kindly request that all mobile phones and similar devices will be turned to silent mode before entering a session.

NAME BADGE

A badge is required for admittance to all World Health Summit sessions and events. Each participant is asked to present the badge in order to gain access to the venue.

PEOPLE WITH DISABILITIES

The venue is accessible to participants with disabilities. Please contact the Secretariat for assistance: Phone: +49 30 49855031 or contact@worldhealthsummit.org
LOST AND FOUND

Lost items can be collected at the registration desk during the World Health Summit. Any objects found during the event and not claimed will remain at the venue.

LIVE-STREAM / WEBCASTS

All keynotes and panel discussions will be available as live-stream at www.worldhealthsummit.org

Recorded webcasts will be available online after the event.

PARKING

An underground parking lot right at the venue is available.

PROGRAM CHANGES

The organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances. Please check the website for regular updates. The organizers reserve the right to cancel, postpone, relocate or change any of the sessions.

POSTERS

A poster exhibition will be located at the poster area in front of Saal 7 | Elizabeth Blackwell.

PUBLIC TRANSPORTATION

Berlin’s public transport provides safe and comfortable rides to almost all destinations in the city. Tickets can be purchased directly at most train stations and in all busses.

More information: www.bvg.de

REGISTRATION

The registration desk is open during the following times:

- Sunday, October 15, 2017 08:00 – 22:00
- Monday, October 16, 2017 08:00 – 22:00
- Tuesday, October 17, 2017 08:00 – 19:00

SMOKING POLICY

It is forbidden to smoke in any part of the World Health Summit venue.
**SPEAKER CENTER**

All speakers and presenters must report to the Speaker Center, located on the first floor, opposite of the entrance, at least two hours prior to their presentation in order to check and upload their presentation. Please provide the data on a USB memory stick or a CD-ROM. Please note that you cannot run the presentation from your personal laptop in the session room. Video support is at the sole responsibility of the speaker.

The Speaker Center is open during the following times:

- **Sunday, October 15, 2017** 08:00 – 18:00
- **Monday, October 16, 2017** 08:00 – 18:00
- **Tuesday, October 17, 2017** 08:00 – 18:00

---

**TAXIS**

All official taxis are colored off-white with a yellow taxi sign on the roof. The meter starts at a set minimum price.

Major Taxi Hotlines:
- **Taxi Berlin**  +49 30 202020
- **Taxi Würzelfunk**  +49 30 210101
- **Taxi Funk**  +49 30 443322

If there is no taxi available, please ask the registration desk staff for assistance.

---

**TRAINING COURSE**

Visiting physicians are accredited 6 points per day by the Berlin Chamber of Physicians. Please refer to the registration desk for further information.
BERLIN - A METROPOLIS FOR SCIENCE

Berlin’s success as a health capital reflects a 300-year tradition as a healthcare and scientific centre. More than a dozen Nobel Prize winners worked here, including researchers such as Rudolf Virchow and Robert Koch. One of Berlin’s most famous medical institutions is the renowned Charité, Europe’s largest university hospital and one of Germany’s leading hospitals. World-renowned scientists of the Charité cooperate closely with recognised research organisations such as the Johns Hopkins Bloomberg School of Public Health in Baltimore. Other famous examples are the German Heart Centre - a top-level hospital for heart and vascular diseases - or Germany’s largest hospital group Vivantes.

Medical care at the highest level requires a strong collaboration between scientists and practitioners. Berlin is a leading centre of science and research in Europe, especially focusing on medicine. Four universities, the Charité teaching hospital, seven universities of applied sciences and over 30 private universities offer teaching and research facilities for people from all over the world. Germany’s most important research organizations such as the Fraunhofer-Gesellschaft or the Max Planck Society are based in Berlin and successful technology parks like the tech-hub Adlershof or biotech park Campus Berlin-Buch established here.

This environment also makes Berlin a popular destination for international congresses in science and medicine: twenty per cent of the approximately 64,000 meetings, conventions and events held in the first half of 2017 were in the fields of medicine, healthcare and pharmaceuticals. International conferences such as the World Health Summit show that the German capital has been able to consolidate its strong position as a destination for medical events.
Along with scientific conferences, Berlin also provides varied cultural experiences. From ancient art by the Old Masters to avant-garde design, from classical opera to musicals to pop concerts, Berlin’s cultural calendar leaves nothing to be desired. For all seasons, at all hours and for every taste, Berlin has something to offer - 365 days a year, 24 hours a day. Visitors to the capital can choose from around 1,500 events a day.

Culture and art enthusiasts can also admire new styles and prominent works from all eras every day in Berlin’s over 180 museums and approximately 440 galleries. The city’s best known museums include the five buildings at Museum Island (Museumsinsel), which is in the historic centre. All buildings display valuable artistic treasures from 3,000 years of human history, e.g. the famous bust of Nefertiti in the New Museum, while the New National Gallery and Martin-Gropius-Bau present contemporary art.

Berlin is the world’s only city to have three opera houses: the Berlin State Opera (Berliner Staatsoper), the Deutsche Oper and the Komische Oper. Classical music lovers can choose from a repertoire of famous works, such as Mozart’s Don Giovanni, or new and experimental operas. Apart from these opera houses, the city’s eight large orchestras, including the world famous Berlin Philharmonic conducted by Sir Simon Rattle, also make for high-class musical enjoyment.

Among the cultural highlights this year is “The Luther Effect. 500 Years of the Reformation”. To mark the 500th anniversary of the reformation the Deutsches Historische Museum features an exhibition at the Martin-Gropius-Bau on the times of the reformation and the impacts of Protestantism around the world until today.

Spectacular lighting design, extravagant costumes by designer Jean-Paul Gaultier, and a story that gets under your skin: All that and more are on offer in “The One Grand Show”, the most elaborate show in Europe. More than 100 dancers and collages are used to create breath-taking scenes.

For more events, visit www.365-24.berlin
<p>| A  | Achtman, Mark 117 | Ackland, Helen 139 | Adelhardt, Michael 123 | Agyeman-Manu, H.E. Kwaku 131 | Albiez, Peter 97 | Alladi, Suvarna 71 | Aslanyan, Garry 105 | Aufmuth, Martin 89 |
| B  | Balabanova, Dina 139 | Banda, Geoffrey 105 | Baptista Leite, Ricardo 83 | Bärnighausen, Till 45 | Barratt, Jane 95 | Baskozos, Giannis 65 | Baumann, Michael 47, 81 | Baumann, Werner 73 |
| C  | Calvignac-Spencer, Sebastien 117 | Campos Fernandes, Adalberto 93 | Canvy, Ben 139 | Capobianco, Emanuele 99 | Castro González de Vega, Cristina 129 | Chan, Chang-Chuan 51 | Chen, Ya-mei 51 | Chua, Arlene 119 |
| D  | Dain, Katie 53 | Dardel, Frédéric 139 | Deák, István 89 | Debe, Siaka 105 | Delaney, David 77 | Depoux, Anneliese 55 | Dhatt, Roopa 43 | Dierkes, Carsten 89 |
| E  | Eckardt, Kai-Uwe 51 | Edwards, Danny 115 | Eggermont, Alexander 81 | Eigen, Peter 133 | Einhäuser, Karl Max 71 | Ellis, Martin 129 | Emmerling, Thea 59 |
| F  | Fanjul, Gonzalo 91 | Farmer, Jillann 85 | Fedorov, Maxim 77 | Flahault, Antoine 55 | Francois, Philippe 129 | Franz, Christoph 73 | Frohloff, Astrid 135 | Fukuhara, Shunichi 51 |
| G  | Galea, Gauden 53 | Galvão, Luiz Augusto 91 | Ganten, Detlev 73, 107 | Garrett, Laurie 97 | Gerlach, Stefanie 83 | Germann, Stefan 57 | Gerzer, Rupert 49 | Ghosh, Shiulie 47 |
| H  | Habisch, André 89 | Hachinski, Vladimir 71 | Hacker, Jörg 55 | Haggenmüller, Christian 85 | Hamilton, Vida 103 | Hanefeld, Johanna 65, 139 | Hansson, Bill S. 113 | Harirchi, Iraj 115 |
| I  | Ikeke, Chikwe 131 | Ischinger, Wolfgang 97 | | | | | | |
| J  | Jack, Andrew 53 | Jafarian, Ali 41 | Jamison, Dean 87, 99 | Joanette, Yves 71 | | | | |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jones, Andrew</td>
<td>137</td>
</tr>
<tr>
<td>Jordan-Harder, Brigitte</td>
<td>137</td>
</tr>
<tr>
<td>Jordan, Neil</td>
<td>87</td>
</tr>
<tr>
<td>Kaidl, Arthur</td>
<td>57</td>
</tr>
<tr>
<td>Kale, Anita</td>
<td>101</td>
</tr>
<tr>
<td>Kaonga, Nadi</td>
<td>123</td>
</tr>
<tr>
<td>Katsuno, Kei</td>
<td>99</td>
</tr>
<tr>
<td>Kaufmann, Stefan</td>
<td>121</td>
</tr>
<tr>
<td>Keller, Christian</td>
<td>89</td>
</tr>
<tr>
<td>Khachaturian, Zaven</td>
<td>71</td>
</tr>
<tr>
<td>Khelef, Nadia</td>
<td>119</td>
</tr>
<tr>
<td>Kibachio, Joseph</td>
<td>47, 53</td>
</tr>
<tr>
<td>Kickbusch, Ilona</td>
<td>41, 115, 127</td>
</tr>
<tr>
<td>Klag, Michael J.</td>
<td>87</td>
</tr>
<tr>
<td>Knieps, Franz</td>
<td>69</td>
</tr>
<tr>
<td>Knufmann-Happe, Karin</td>
<td>135</td>
</tr>
<tr>
<td>Köhler, Carsten</td>
<td>79</td>
</tr>
<tr>
<td>Kornberg, Roger D.</td>
<td>73</td>
</tr>
<tr>
<td>Kosch, Markus</td>
<td>67</td>
</tr>
<tr>
<td>Kowalski, Corinne</td>
<td>55</td>
</tr>
<tr>
<td>Krause, Johannes</td>
<td>117</td>
</tr>
<tr>
<td>Kraus, Joseph</td>
<td>133</td>
</tr>
<tr>
<td>Kreh, Rüdiger</td>
<td>69, 129, 135</td>
</tr>
<tr>
<td>Kriwet, Carla</td>
<td>93</td>
</tr>
<tr>
<td>Krüger, Susanna</td>
<td>111</td>
</tr>
<tr>
<td>Kühne, Titus</td>
<td>123</td>
</tr>
<tr>
<td>Kümmerle, Björn</td>
<td>59</td>
</tr>
<tr>
<td>Kurth, Tobias</td>
<td>139</td>
</tr>
<tr>
<td>Kurzai, Oliver</td>
<td>103</td>
</tr>
<tr>
<td>Kuyumdzhieva, Albena</td>
<td>77</td>
</tr>
<tr>
<td>Lærdal, Tore</td>
<td>101</td>
</tr>
<tr>
<td>Lahtinen, Eero</td>
<td>59</td>
</tr>
<tr>
<td>Lajeunesse, Yvette</td>
<td>51</td>
</tr>
<tr>
<td>Lamara, Farid</td>
<td>137</td>
</tr>
<tr>
<td>Langenbacher, Anja</td>
<td>99</td>
</tr>
<tr>
<td>Larson, Heidi J.</td>
<td>95, 121</td>
</tr>
<tr>
<td>Laur, Thomas P.</td>
<td>93</td>
</tr>
<tr>
<td>Litman, Gilles</td>
<td>83</td>
</tr>
<tr>
<td>Liu, Depei</td>
<td>49</td>
</tr>
<tr>
<td>Liu, Joanne</td>
<td>73</td>
</tr>
<tr>
<td>Lohse, Martin J.</td>
<td>61, 63</td>
</tr>
<tr>
<td>Loures, Luiz</td>
<td>131</td>
</tr>
<tr>
<td>Madelin, Robert</td>
<td>59</td>
</tr>
<tr>
<td>Maduwayne, Kalana</td>
<td>Prasad 89</td>
</tr>
<tr>
<td>Mamdani, Masuma</td>
<td>91</td>
</tr>
<tr>
<td>Matthews, Mary</td>
<td>89</td>
</tr>
<tr>
<td>Mazigo, Humphrey D.</td>
<td>79</td>
</tr>
<tr>
<td>McCarthy, Justin</td>
<td>127</td>
</tr>
<tr>
<td>McKee, Martin</td>
<td>59</td>
</tr>
<tr>
<td>Melesse, Tewodros</td>
<td>111</td>
</tr>
<tr>
<td>Messner, Angelika</td>
<td>117</td>
</tr>
<tr>
<td>Mired of Jordan, HRH</td>
<td>Princess Dina 47, 53</td>
</tr>
<tr>
<td>Moeti, Matshidiso</td>
<td>41, 127</td>
</tr>
<tr>
<td>Molyneux, David</td>
<td>79</td>
</tr>
<tr>
<td>Moon, Suerie</td>
<td>69</td>
</tr>
<tr>
<td>Möröy, Tarik</td>
<td>63</td>
</tr>
<tr>
<td>Mshinda, Hassan</td>
<td>57</td>
</tr>
<tr>
<td>Müller, Gerd</td>
<td>127</td>
</tr>
<tr>
<td>Mundel, Trevor</td>
<td>45</td>
</tr>
<tr>
<td>Nanyombi, Margaret</td>
<td>89</td>
</tr>
<tr>
<td>Napier, David</td>
<td>117</td>
</tr>
<tr>
<td>N’Cho, Dagnan</td>
<td>115</td>
</tr>
<tr>
<td>Neidhardt, Harald</td>
<td>89</td>
</tr>
<tr>
<td>Nestulia, Viktor</td>
<td>133</td>
</tr>
<tr>
<td>Ngoma, Twalib</td>
<td>67</td>
</tr>
<tr>
<td>Nicotera, Pierlugi</td>
<td>81</td>
</tr>
<tr>
<td>Nimmesgern, Elmar</td>
<td>49, 93</td>
</tr>
<tr>
<td>Nusser, Harald</td>
<td>45</td>
</tr>
<tr>
<td>Oduyebo, Olawunmi</td>
<td>43</td>
</tr>
<tr>
<td>Oelrich, Stefan</td>
<td>53</td>
</tr>
<tr>
<td>Olesen, Ole F.</td>
<td>105</td>
</tr>
<tr>
<td>Ong, Hian Tat</td>
<td>101</td>
</tr>
<tr>
<td>Paikan, Feda Mohammad</td>
<td>85</td>
</tr>
<tr>
<td>Paterson, Pauline</td>
<td>95</td>
</tr>
<tr>
<td>Penk, Andreas</td>
<td>67</td>
</tr>
<tr>
<td>Piot, Peter</td>
<td>121</td>
</tr>
<tr>
<td>Pries, Axel Radlach</td>
<td>111</td>
</tr>
<tr>
<td>Pshenichnaya, Natalia</td>
<td>123</td>
</tr>
<tr>
<td>Quinn, Laura</td>
<td>83</td>
</tr>
<tr>
<td>Radbruch, Andreas</td>
<td>63</td>
</tr>
<tr>
<td>Rajewsky, Nikolaus</td>
<td>61</td>
</tr>
<tr>
<td>Ralston, Johanna</td>
<td>83</td>
</tr>
<tr>
<td>Razzaq, Saadiya</td>
<td>91</td>
</tr>
<tr>
<td>Rebiere, Ophra</td>
<td>115</td>
</tr>
<tr>
<td>Rees-Sidhu, Charlotte</td>
<td>43</td>
</tr>
<tr>
<td>Regateiro, Fernando</td>
<td>51</td>
</tr>
<tr>
<td>Reinhard-Rupp, Jutta</td>
<td>79, 105</td>
</tr>
<tr>
<td>Ricciardi, Walter</td>
<td>65</td>
</tr>
<tr>
<td>Rocklœv, Joacim</td>
<td>55</td>
</tr>
<tr>
<td>Rosling, Ola</td>
<td>77</td>
</tr>
<tr>
<td>Röttger, Maike</td>
<td>99</td>
</tr>
<tr>
<td>Rühli, Frank</td>
<td>113</td>
</tr>
<tr>
<td>Salama, Peter</td>
<td>97</td>
</tr>
<tr>
<td>Samake, Salif</td>
<td>123</td>
</tr>
<tr>
<td>Sanghvi, Bhaumik</td>
<td>89</td>
</tr>
<tr>
<td>Santerre, Frédérique</td>
<td>129</td>
</tr>
<tr>
<td>Saso, Luciano</td>
<td>65</td>
</tr>
<tr>
<td>Schaade, Lars</td>
<td>119</td>
</tr>
<tr>
<td>Schäfers, H.E. Reinhard</td>
<td>65</td>
</tr>
<tr>
<td>Schäuble, Ulrich</td>
<td>103</td>
</tr>
<tr>
<td>Schmitt-Lord, Thimo V.</td>
<td>88</td>
</tr>
<tr>
<td>Schönweitz, Raphael</td>
<td>89</td>
</tr>
<tr>
<td>Schrade, Christina</td>
<td>99</td>
</tr>
<tr>
<td>Schräpel, Norman</td>
<td>123</td>
</tr>
<tr>
<td>Schultze, Joachim L.</td>
<td>61</td>
</tr>
<tr>
<td>Schütte, Georg</td>
<td>87</td>
</tr>
<tr>
<td>Segurado, Aluisio Cotrim</td>
<td>79</td>
</tr>
<tr>
<td>Senaratne, Rajitha</td>
<td>53</td>
</tr>
<tr>
<td>Sendegeya, Augustin</td>
<td>137</td>
</tr>
<tr>
<td>Seybold, Joachim</td>
<td>65</td>
</tr>
<tr>
<td>Shengelia, Bakhuti</td>
<td>131</td>
</tr>
<tr>
<td>Shih, Chih-Yuan</td>
<td>51</td>
</tr>
<tr>
<td>Silva, João Gabriel</td>
<td>93, 107</td>
</tr>
<tr>
<td>Singh, Sonia</td>
<td>43</td>
</tr>
<tr>
<td>Sipido, Karin R.</td>
<td>49</td>
</tr>
<tr>
<td>Sowah, Mohammed Adjei</td>
<td>41</td>
</tr>
<tr>
<td>Spiegel, Andrew</td>
<td>47</td>
</tr>
<tr>
<td>Spranger, Joachim</td>
<td>83</td>
</tr>
<tr>
<td>Stier, Anna Babette</td>
<td>87</td>
</tr>
<tr>
<td>Stöckl, Heidi</td>
<td>65</td>
</tr>
<tr>
<td>Stokes, Robert J.</td>
<td>119</td>
</tr>
<tr>
<td>Stone, Anne C.</td>
<td>117</td>
</tr>
<tr>
<td>Sullivan, Richard</td>
<td>85</td>
</tr>
<tr>
<td>Sy, Elhadj As</td>
<td>127</td>
</tr>
</tbody>
</table>
S P E A K E R  I N D E X

Takian, Amirhossein 115, 139
Tarakji, Ahmad 65, 111
Theis, Fabian 61
Theobald, Sally 43
Thompson, Kelly 43
Told, Michaela 91

Takian, Amirhossein 115, 139
Tarakji, Ahmad 65, 111
Theis, Fabian 61
Theobald, Sally 43
Thompson, Kelly 43
Told, Michaela 91

Vega, Pablo 91
Verschure, Paul 113
Vogel, Jörg 61
Voigt, Wieland 81
von Bernuth, Horst 95
Vong, Sreytouch 43
Vyas, Akanksha 89

Warnken, Heiko 137
Wasunna, Monique 79
Watkins, Kevin 115
Weber-Mosdorf, Susanne 69
Weigand, Markus 103
Wieczorek-Zeul, Heidemarie 43
Wieler, Lothar H. 45, 113
Wiestler, Otmar D. 49
Wuliji, Tana 43

Yang, Dazhu 131

Zaman, Muhammad H. 55
Zielonka, Juliane 123
Zuniga, José 41

A
Access Accelerated

B
Bayer Science & Education Foundation
Berlin Institute of Health (BIH)
Bundeswehr Command and Staff College

C
Center for Global Health Engagement (CGHE)
Centre Virchow-Villermé for Public Health Paris-Berlin
Charité - Universitätsmedizin Berlin
Coalition for Epidemic Preparedness Innovations (CEPI)

D
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ)

E
European and Developing Countries Clinical Trials Partnership (EDCTP)
European Commission
European ESTHER Alliance
European Resuscitation Council (ERC)
European School of Management and Technology (ESMT)

F
F. Hoffmann-La Roche Ltd.
Fondation Botnar
Foundation for Innovative New Diagnostics (FIND)

G
German Association of Research-based Pharmaceutical Companies (VFA)
German Centers for Health Research (DZG)
German Federal Ministry for Economic Cooperation and Development (BMZ)
German Healthcare Partnership (GHP)
German National Academy of Sciences Leopoldina e.V.
German Network against Neglected Tropical Diseases (DNTDs)
German Resuscitation Council (GRC)
<table>
<thead>
<tr>
<th>H</th>
<th>Harvard Medical School</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heidelberg Institute of Public Health (HIPH)</td>
<td></td>
</tr>
<tr>
<td>Helmholtz Association of German Research Centers e.V.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I</th>
<th>Institut de Recherches Cliniques de Montréal (IRCM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>InterAcademy Partnership (IAP) for Health</td>
<td></td>
</tr>
<tr>
<td>International Committee of the Red Cross (ICRC)</td>
<td></td>
</tr>
<tr>
<td>International Development Research Centre (IDRC)</td>
<td></td>
</tr>
<tr>
<td>International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>J</th>
<th>Johns Hopkins Bloomberg School of Public Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint United Nations Programme on HIV/AIDS (UNAIDS)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>K</th>
<th>King's College London</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyoto University</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>L</th>
<th>Leibniz Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>London School of Hygiene and Tropical Medicine (LSHTM)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M</th>
<th>M8 Alliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max Delbrück Center for Molecular Medicine (MDC)</td>
<td></td>
</tr>
<tr>
<td>Max Planck Institute for Infection Biology</td>
<td></td>
</tr>
<tr>
<td>Max Planck Society</td>
<td></td>
</tr>
<tr>
<td>Merck</td>
<td></td>
</tr>
<tr>
<td>Monash University</td>
<td></td>
</tr>
<tr>
<td>Munich Security Conference (MSC)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N</th>
<th>National Taiwan University (NTU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National University of Singapore (NUS)</td>
<td></td>
</tr>
<tr>
<td>Novartis AG</td>
<td></td>
</tr>
</tbody>
</table>

| P | Pfizer Inc |

| R | Robert Koch Institute |

<table>
<thead>
<tr>
<th>S</th>
<th>Sanofi</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP SE</td>
<td></td>
</tr>
<tr>
<td>Sapienza University</td>
<td></td>
</tr>
<tr>
<td>Scientific Panel for Health (SPH)</td>
<td></td>
</tr>
<tr>
<td>SEEK Development, Strategic and Organizational Consultants GmbH</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T</th>
<th>Tehran University of Medical Sciences</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Graduate Institute of International and Development Studies</td>
<td></td>
</tr>
<tr>
<td>The NCD Alliance</td>
<td></td>
</tr>
<tr>
<td>Transparency International</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U</th>
<th>Université Paris Descartes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Université Sorbonne Paris Cité</td>
<td></td>
</tr>
<tr>
<td>University Hospital of Cologne</td>
<td></td>
</tr>
<tr>
<td>University of Coimbra</td>
<td></td>
</tr>
<tr>
<td>University of Geneva</td>
<td></td>
</tr>
<tr>
<td>University of Montreal</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>W</th>
<th>Women in Global Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>World Dementia Council (WDC)</td>
<td></td>
</tr>
<tr>
<td>World Health Organization (WHO)</td>
<td></td>
</tr>
<tr>
<td>World Stroke Organization (WSO)</td>
<td></td>
</tr>
</tbody>
</table>
### SPONSORING PARTNERS

<table>
<thead>
<tr>
<th>Strategic Partners</th>
<th>Major Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARITÉ</td>
<td>BERLIN INSTITUTE OF HEALTH</td>
</tr>
<tr>
<td>SANOFI</td>
<td>Microsoft</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td></td>
<td>Roche</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>General Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer Science &amp; Education Foundation</td>
</tr>
<tr>
<td>Federal Ministry of Health</td>
</tr>
<tr>
<td>HELMHOLTZ ASSOCIATION</td>
</tr>
<tr>
<td>DZG DEUTSCHE ZENTREN DER GESUNDHEITSFORSCHUNG</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
</tr>
<tr>
<td>Medtronic</td>
</tr>
<tr>
<td>Merck</td>
</tr>
<tr>
<td>Novartis</td>
</tr>
<tr>
<td>SAP</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
</tr>
</tbody>
</table>
**Media Registrations**

Media Registrations are available free of charge to journalists (pending proof of affiliation). Prior to the World Health Summit, please apply for your registration online via www.worldhealthsummit.org/media/accreditation.

During the event, please contact the media accreditation counter at the registration desk.

**Media Access**

Media has access to all official sessions of the World Health Summit.

**Press Area**

First floor, opposite of the venue entrance

The press area can be used during the whole World Health Summit.

---

**PRESS CONTACT**

Tobias Gerber & Daniela Levy
tobias.gerber@charite.de
daniela.levy@charite.de
Tel.: +49 30 450 572 114

**PRESS CONFERENCE**

Sunday, October 15, 15:00–15:45
Saal 7 | Elizabeth Blackwell
WHS Foundation GmbH
c/o Charité -
Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin, Germany

Managing Directors
Jörg Heldmann
joerg.heldmann@charite.de
Tel.: +49 30 450 572 118
Fax: +49 30 450 517 911

Alexander Hewer

Strategic Communications Director
Daniela Levy
daniela.levy@charite.de
Tel.: +49 30 450 572 114
Fax: +49 30 450 517 911

PA to the Managing Director
Petra Neitzel
petra.neitzel@charite.de
Tel.: +49 30 450 572 219
Fax: +49 30 450 517 911

Press & Public Relations Director
Tobias Gerber
tobias.gerber@charite.de
Tel.: +49 30 450 572 114
Fax: +49 30 450 517 911

Project Manager
Nicole Rudolph

World Health Summit Presidents
Hélène Boisjoly
Detlev Ganten

PA to the Founding President
Pascale Schulte
pascale.schulte@charite.de
Tel.: +49 30 450 572 102
Fax: +49 30 450 517 911

Registration Department
Felix Heller, Kristin Keller

Organizing Secretariat
Agentur WOK GmbH
Palisadenstraße 48
10243 Berlin, Germany

www.worldhealthsummit.org
Photo Credits
Angela Merkel, Page 8 © Bundesregierung | S. Kugler
Potsdamer Platz, Berlin, Page 11 © iStockphoto | andrearoad
Karl Max Einhäupl, Axel Radlach Pries, Astrid Lurati, Ulrich Frei,
Page 14 & 15 © Charité – Universitätsmedizin Berlin
Rolf Zettl, Page 15 © David Ausserhofer | Helmholtz
Martin Lohse, Page 15 © Bettina Flitner | MDC
Bärbel-Maria Kurth, Page 21 © Robert Koch Institute | Dugnus
Eckart von Hirschhausen, Page 22 © Frank Eidel
Otmar D. Wiestler, Page 49 © DKFZ
Kosmos, Page 19, 145 © Kosmos KG
Hermann Gröhe, Page 32, 73, 107 © Jochen Zick (action press)
Peter Albiez, Page 97 © Pfizer Deutschland GmbH
Panorama Berlin, Page 150 © visitBerlin | Wolfgang Scholvien
Konzerthaus Berlin, Page 151 © visitBerlin | Gutscherra/Osthoff

Layout
Eta Friedrich, Berlin

Printer
Laserline, Berlin
World Health Summit

WHS Foundation GmbH
c/o Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Germany

Tel.: +49 30 450 572102
Fax: +49 30 450 572911

secretariat@worldhealthsummit.org
www.worldhealthsummit.org
SAVE THE DATES

WORLD HEALTH SUMMIT
BERLIN, GERMANY
OCTOBER 14–16, 2018

WORLD HEALTH SUMMIT
REGIONAL MEETING
COIMBRA, PORTUGAL
APRIL 19–20, 2018

WORLD HEALTH SUMMIT
BERLIN, GERMANY
OCTOBER 14–16, 2018

www.worldhealthsummit.org